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Preface of the first volume 
The evaluation of the exposure of workers to dangerous agents is one of the measures 
insuring a better health protection. This evaluation is called monitoring. 
Two approaches are available for the monitoring : 
- ambient monitoring already in use for many years and 
- biological monitoring of more recent development. 
The  need for clear definitions and  for establishing the  respective roles  of these two 
types of monitoring  has  become  necessary  recently.  In  1980 in  Luxembourg  at an 
international seminar organized jointly by the CEC  and the  United States authorities 
(Occupational  Safety  and  Health  Administration  and  the  National  Institute  for 
Occupational Safety and Health) on the Assessment of Toxic Agents at the Workplace, 
the following definitions were agreed : 
- ambient  monitoring  is  the  measurement  and  assessment  of  agents  at  the 
workplace  and  evaluates  ambient  exposure  and  health  risk  compared  to  an 
appropriate reference; 
- biological monitoring is the measurement and assessment of workplace agents 
or  their  metabolites  either  in  tissues,  secreta,  excreta,  expired  air  or  any 
combination  of  these  to  evaluate  exposure  and  health  risk  compared  to  an 
appropriate reference. 
In  addition, the term "Health Surveillance" was also defined as the periodic medico-
physiological examinations of exposed workers with the objective of protecting health 
and preventing occupational related disease. The detection of established disease is 
outside the scope of this definition. 
The definitions of biological monitoring and health surveillance separate components 
of a continuum which can range from the measurements of agents in the body through 
measurements of metabolites,  to  signs of early disease.  A problem  left unresolved 
concerns the precise place within these definitions of certain biochemical tests such 
as  zinc  protoporphyrin  (ZPP),  delta  aminolaevulinic  acid  dehydrase  (ALA-D),  delta 
aminolaevulinic acid (ALA) in the blood and urine, etc., which are, in fact, indicators of 
metabolic effects which have occurred as a consequence of exposure. 
Ambient monitoring is carried out for different reasons, for example : 
a.  determining ambient concentrations in  relation to an  established legal standard or 
consensus guideline; 
b.  determining the  relationship,  if any,  between the concentrations of agents at the 
workplace and the health of the workers; 
c.  ensuring the effectiveness of control measures; 
d.  evaluating the need for controls in the vicinity of specific emission sources; 
e.  indicating trends in relation to an improvement or determination at the workplace; 
f.  providing an historical record. 
Biological monitoring measures or evaluates exposure from all  routes.  It  sometimes 
allows a better evaluation of health risk than ambient monitoring especially in  cases 
where exposure through different routes has to be considered. 
Biological  monitoring takes  into account individual  variability,  the  impact of factors 
such as personal activity, biological characteristics and life styles of the individual. IV 
The  two  types  of  monitoring  are  complementary  in  increasing  the  protection  of 
workers'  health.  If  both  are  carried  out  simultaneously,  information  should  be 
produced on the relationships existing between external exposure and concentration 
of  the  substance  in  biological  samples,  and  between  this  concentration  and  early 
effects. 
Detailed knowledge of the metabolism of the toxic agent in the human organism and of 
the alterations that occur in the critical organ is essential in selecting the parameter to 
be used as indicator. 
Unfortunately,  however,  such  knowledge  is  usually insufficient and  thus  limitations 
exist in most biological monitoring programmes. 
The conditions necessary for successful biological monitoring are: 
- existence of indicators, 
- existence of analytical methods that will guarantee technical reliability in the use of 
these indicators, 
- possibility of measuring the indicators on readily accessible biological specimens, 
- existence and knowledge of dose-effect and dose-response relationships. 
In carrying out a biological monitoring programme, it is indispensable to know exactly 
what the characteristics and behaviour of the indicators under study are in relationship 
to  length  of  exposure,  time  elapsed  since  beginning  and  end  of  exposure,  and  all 
physiological  and  pathological  factors  other  than  exposure  that  could  give  a  false 
interpretation of the results obtained. 
Conditions for biological monitoring application include adoption of analytical methods 
yielding values comparable throughout the different laboratories. 
This long time adopted approach has already permitted the CEC to standardize in 1972 
a  method  for  erythrocyte  ALAD  determination  and  develop  programmes  for  inter-
laboratory comparisons for lead and cadmium determination in biological media. 
The  Council of Ministers of the  European Communities in  adopting  in  1978 the  First 
Action  Programme  on  Safety  and  Health  at  Work  proposed  by  the  Commission 
stressed  the  need  to  increase  protection  against  dangerous  substances;  it 
emphasized  the  need  to  promote  new  monitoring  and  measuring  methods  for  the 
assessment of individual exposure,  in  particular through the  application of sensitive 
biological indicators. 
In August 1982 the Council adopted a directive on the protection of workers exposed to 
lead. The  monitoring of blood lead levels as well as the determination of ALAU, ALAD 
and  ZPP  are among the tools to  be  used  for monitoring worker exposure to lead.  A 
comparison of the results with action levels and limit values allows appropriate action 
to be taken. 
Considerable  data  concerning  the  biological  monitoring  of  a  number  of  industrial 
chemicals has been published in the international literature. 
Nevertheless,  the  difference  in  approaches  used  in  the  research,  the  variety  of 
analytical  methods  and  the  frequent  discordances  in  the  results,  usually  make  it 
difficult to formulate a conclusive synthesis permitting the transfer of literature data 
into practice. 
The aim of this series dedicated to human biological monitoring of industrial chemicals 
in  occupational  health  is  based  on  the  considerable  experience  acquired  by  the 
authors in the specific topics. 
For the draft of the monographs, the following outline, suggested by R.L.  Zielhuis and 
R.  Lauwerys, has been used : 
- a review of metabolism and/or mechanism of action; 
- potentially  useful  biological  parameters  for  evaluation  of  exposure  and/or  body 
burden and/or early reversible effects; 
- a critical evaluation of each parameter : 
predictive validity in regard to exposure; 
quantitative  relationship  between  levels  of  external  exposure  and  internal 
exposure, and between exposure and effects; 
limitations of the test; 
- a proposal for one or several tests for biological monitoring. 
Because of the considerable gaps in  scientific knowledge it has not been possible to v 
follow this  outline strictly in  every single one  of  the  monographies.  It  is  hoped  that 
future research will fill these gaps. 
It  must be  recognized that the biological monitoring approach for other toxic agents 
must still be developed and that considerable research is still necessary. 
The Council in  the above mentioned action programme and  in  the directives recently 
adopted in this field stressed the need to provide adequate information at all  levels. It 
is  considered  that  these  monographs  will  be  of  benefit  to  the  occupational  health 
physicians,  the  industrial  hygienists,  the  employers  and  the  trade-union 
representatives,  by  giving  the  scientific  rationale  on  which  a  number  of  biological 
monitoring programmes are based. 
The  Editors 
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Preface of the second volume 
Last year we published a series of monographs in  one volume under the title  "Human 
biological monitoring of industrial chemicals series" in which Benzene, Cadmium Chlorinated 
Bydrocarbon solvents,  Lead,  Manganese,  Titanium  and Toluene were discussed. 
When  preparing these documents each author was asked to pay particular attention to 
the problem of the quantitative relationships between the levels of external and internal 
exposure and between exposure and effects. 
In a number of cases information on the levels of biological indicators which are indicative 
of current exposure without short term  detectable health effects is  available. 
However we were already confronted with the impossibility to determine at present if the 
levels for  biological  indicators without short term  detectable health  effects can also  be 
considered as  adequate with  respect to longer term effects. 
In preparing the present series of monographs it became apparent that for a number of 
biological indicators corresponding to biochemical tests, it is not yet possible to establish 
if these are indicative of early reversible effects and would thus qualify for terminology of 
"biological monitoring" as defined in the preface of the first volume. For many substances, 
extensily used in industry, biological indicators are being developed but still require extensive 
assessment before possible routine application. 
As the object of these monographs is to provide up to date scientific information not only 
for the chemical substances for which biological indicators could be rised routine, but also 
for the many more substances for which  biological  indicators are at the early stage of 
development it was considered advisable to change the title of the series to "Biological 
indicators  for the  assessment  of  human  exposure to  industrial  chemicals". 
We  hope that this new title will  avoid  giving the impression to the reader that for all  the 
substances presented in this volume and the substances ones,  biological indicators can 
be already routinely applied. 
The  Editors 
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Preface of the third volume 
Following the established yearly frequency, we are happy to present the third volume in 
the series of monographs on  II Biological Indicators for the Assessment of Human Exposure 
to Industrial Chemicals", which are addressed to occupational health physicians, industrial 
hygienists and,  in  general, to all  who are concerned with  prevention in  the workplace. 
The original title of the first volume of the series II Human Biological Monitoring of Industrial 
Chemicals Series"  was changed in the second volume and this change is  now further 
justified  by the four  monographs making up the third  volume : alkyl  lead  compounds, 
dimethylformamide, mercury and organophosphorus pesticides. 
As in the previous volumes, the scope of the publication has not been limited to the most 
widely known and used toxic industrial agents.  It was felt that consideration should also 
be given to other substances, where recent scientific advances have suggested the need 
to verify how far assessment of exposure using biological indicators is reliable in real industrial 
situations. One of the aims of this series is, in fact, to stimulate further research, especially 
applied  research,  that would  have the task of validating,  on  large groups of workers, 
preliminary scientific observations that are usually obtained from studies on relatively small 
groups of subjects and often  in  controlled experimental exposure situations. 
Eighteen monographs have now appeared in  this series published by the Commission 
of the European Communities. The previous two volumes covered fourteen monographs 
on  acrylonitrile,  aluminium,  benzene,  cadmium,  chlorinated  hydrocarbon  solvents, 
chromium, copper,  lead,  manganese,  styrene,  titanium, toluene,  xylene,  zinc. 
Highly competent scientists from the following European scientific and research institutes 
have  contributed  in  preparing  the  monographs:  Cattedra  di  Medicina  del  Lavoro 
deii'Universita di  Parma (Italy),  Clinica del Lavoro "L. Devoto" deii'Universita di  Milano 
(Italy),  Coronel  Laboratorium,  Universiteit van  Amsterdam (the Netherlands),  lnstitut fOr 
Arbeits- und Sozialmedizin der Universitat Erlangen-NOrnberg (F.R.  Germany), Unite de 
Toxicologie lndustrielle et Medicale,  Universite de Louvain,  Bruxelles (Belgium). 
It is planned in the future to extend cooperation to other scientific institutes and thus involve 
a wider number of scientists and experts. 
The fourth volume, which is already under way, will include monographs on "Aldrin, Dieldrin 
and Endrin" by N.J. Van Sittert, Shell  lnternationale Petroleum (the Netherlands);  "Non-
Substituted Aliphatic Hydrocarbons" by K.H. Cohz, Danish National Institute of Occupational 
Health, Hellerup (Denmark); "Arsenic" by V.  Foa, Clinica del Lavoro, University of Milan, 
(Italy);  "Vanadium" by K.- H.  Schaller,  lnstitut fOr  Arbeits- und Sozialmedizin,  University 
of Erlangen-NOrnberg (F.R.  Germany). 
The  Editors 
1986 VIII 
Editorial Board 
Prof.  Lorenzo Alessio 
Institute of Occupational  Health 
Clinica del  Lavoro  L.  Devoto 
University of  Milan 
Dr.  Alexander Berlin 
Commission of the European Communities 
Directorate General  Employment and Social  Affairs 
Health  and Safety Directorate 
Luxembourg 
Dr.  Renato Roi 
Dr.  Mirto Boni 
Commission of the European Communities 
Joint Research  Centre - ECDIN  Group 
lspra (VA)  Italy 
List of Authors 
ALKYL  LEAD  COMPOUNDS 
L.  Alessio,  A.  Deii'Orto, A.  Forni 
DIMETHYLFORMAMIDE 
R.  Lauwerys 
MERCURY 
v.  Foa,  G.  Bertelli 
ORGANOPHOSPHORUS  PESTICIDES 
M.  Maroni Contents 
Preface  .....................................................................................................................................................................  Ill 
Alkyl  Lead  Compounds  ......................................................  .... ........ .................................................................  3 
Dimethylformamide  .......................................................  .. .......................................  17 
Me~u~ ....................................................................................  .  .......................................................  29 
Organophosphorus  Pesticides  ......................................................................................................  47 Biological indicators for the
assessment of human exposure
to industrial chemicals
Alkyl Lead Compounds
L. Alessio, A. Dell'Orto, A. Forni5 
Summary 
The main route of absorption of alkyl lead compounds is via the respiratory tract but the 
skin, too, offers an excellent penetration route for both tetraethyllead (TEL) and tetramethyl 
led (TEM).  The toxic effects of alkyl lead compounds involve mainly the central nervous 
system. Only slight alterations in heme synthesis have been demonstrated, which contrasts 
with the situation  in  the case of inorganic lead. 
Lead in urine (PbU) is at present the only biological indicator that can be used for assessment 
of occupational exposure to organic lead compounds. 
Abbreviations 
TEL 
TEM 
PbB 
PbU 
PbU-EDTA 
ALAD 
EP 
ALAU 
CPU 
Tetraethyl  lead 
T  etramethyl lead 
Lead in  blood 
Urinary lead 
Amount of chelatable lead excreted with  24-h  urine after administration 
of CaNa2EDT  A 
Delta-aminolevulinic acid dehydratase activity of erythrocytes 
Erythrocyte protoporphyrin 
Delta-aminolevulinic acid in  urine 
Urinary coproporphyrin 7 
Alkyl  Lead Compounds 
Introduction 
Alkyl lead compounds must be discussed separately from inorganic lead because of the 
quite different mode of absorption, metabolic transformation and pathological pattern which 
involve the central nervous system in particular. Even though a large number of alkyl lead 
compounds exists only tetraethyl lead (TEL)  and tetramethyl lead (TEM)  are of practical 
importance in industry where, due to their exceptional antiknock properties, they are used 
as additive in  petrol for internal combustion engines to increase the "octane number". 
The concentration of alkyl lead compounds in  petrol varies according to the regulations 
in  force in  different countries:  an  EEC  Directive requires that Member States impose a 
maximum lead limit of 0.15 to 0.40 g/1  (1978). 
Alkyl lead compounds used as additive in  petrol constitute one of the largest sources of 
inorganic lead pollution of the air, especially in urban areas. The quantity of organic lead 
compounds emitted with combustion fumes does, however, account for only a small part 
of the metal contained in the petrol (between 0. 70/o  and 1  .1 Ofo)  (Grand  jean and Nielsen, 
1979).  Therefore  the  problem  of  environmental  pollution  due to  the  use  of  alkyl  lead 
compounds as antiknock agents seems to be mostly the result of emission of inorganic 
lead  with  motor  vehicle  exhaust.  However,  a study  by  Nielsen  et  al.  (1978)  revealed 
significantly higher encephalic concentrations of trialkyl lead compounds in  subjects not 
occupationally exposed to  alkyl  lead compounds living in  urban areas,  compared with 
the encephalic concentrations detected in  subjects living in  rural  areas. 
Occupational exposure may occur during the production, transport and  mixing of TEL 
and TEM with gasoline, but only a relatively small number of cases of poisoning has been 
reported  (Grandjean  and  Nielsen,  1979).  Hazardous situations  may  occur during  the 
cleaning of leaded gasoline storage tanks (Kitzmiller et al.,  1954; Akatsuka,  1973). Other 
subjects particularly exposed are filling stations attendants, staff in garages and underground 
parking lots and motor mechanics who use gasoline to clean their hands (Leavitt,  1934; 
Gutniak et al.,  1964). 
Gasoline sniffing has been the cause of several cases of alkyl lead compounds poisoning 
diagnosed among children (Grandjean and  Nielsen,  1979). 
Physico-Chemical Properties 
Tetraethyl  lead 
Formula 
Constants  Molecular weight:  325 
MP:  -136.8°C 
BP:  198 to  202°C with  decomposition 
0: 1.659 at  18°C 
vapour pressure : 1 mm Hg at 38.4°C 
Colourless, oily liquid, pleasant characteristic odour, soluble in benzene, ethyl alcohol and 
ethyl  ether. 8 
T  etramethyl lead 
Formula 
Constants  Molecular weight:  267.33 
MP:  -27.5°C 
BP:  110°C 
0: 1.99 
Vapour pressure:  22 mm Hg at 25°C 
Colourless liquid, slightly soluble in  benzene, ethyl alcohol and ethyl ether. 
Effects on  Humans 
The toxic effects of alkyl  lead compounds involve the central  nervous system. 
Absorption of high quantities of TEL over a short period or of lower quantities over prolonged 
periods gives rise to a pattern of intoxication affecting the nervous system. In the less severe 
forms, the characteristic clinical symptoms are loss of appetite, nausea, metallic taste in 
the mouth, troubled memory and sleep (Hamilton et al.,  1925; Sanders, 1964; Akatsuka, 
1973). As the intoxication progresses, other clinical  symptoms appear (Machle,  1933) : 
the patient undergoes profound character changes, with recurrent episodes of complete 
disorientation, hallucinations, facial muscle contraction, muscular hyperactivity and increased 
resistance to physical fatigue. These episodes may suddenly change to maniacal symptoms 
similar to "delirium tremens" or to violent convulsions that may lead to coma or death. 
The period between the cessation of exposure and appearance of the initial symptoms 
may vary from a few hours in  the most severe,  rapidly evolving cases, to 8-10 days in 
mild cases (Kehoe,  1983). 
The neurological changes that occur during TEL intoxication appear to be in the encephalus. 
Some authors suggest that triethyllead (the toxic metabolite of TEL) acts by inhibiting cell 
respiration,  probably through  uncoupling of  oxidative  phosphorylation  (Cremer,  1959; 
Cremer et al.,  1961;  Nielsen et al.,  1978). 
According to  Galzigna et al.  (1975)  "the action of alkyl  lead derivatives of lead can be 
explained by their multimodal effects on the CNS and particularly by the interference with 
cholinergic, adrenergic and serotonine-ergic processes. The toxic action of triethyl lead 
might be related mainly to a transformation of norepinephrine into an aminochrome which 
is stabilized by acetylcholine leaking from cholinergic neurones after inhibition of pseudo-
cholinesterase. The combined effects result in the formation of a psychotogenic complex 
particularly active at the central  nervous system  level''. 
According to a more recent hypothesis trialkyllead compounds elicit increased neurone 
excitability probably because of a changed distribution of the cr ions via the cell membranes 
(Cremer, 1984). The increased neurone activity gives rise to an increased glucose utilization 
and consequently an accumulation of piruvic and lactic acids.  In addition, TEL and TEM 
may have a direct effect on the mitochondria, inhibiting the entry of substrates (Skilleter, 
1975) and A  TP  synthesis. 
The  neurotoxic action  of diethyl  lead  seems to  be far  less  marked than that of trialkyl 
compounds. 
TEM intoxication appears to resemble TEL intoxication, even though it is usually less severe 
(Sprigman et  al.,  1973; Gething,  1975). 
Up to 1979 about 1  00 cases of fatal TEL intoxication had been reported but no fatal cases 
of TEM  intoxication appear to  have occurred (Grandjean et al.,  1979). 
As  regards  other clinical  effects,  contrary  to  the  situation  with  inorganic  lead,  during 
intoxication  by  alkyl  lead  compounds  no  evidence  of  significant  alterations  in  blood 
chemistry,  abdominal colic or peripheral neuropathy has been  recorded. 
Finally, it has been recently suggested, on an experimental basis, that alkyl lead compounds 
may exert a genotoxic effect. Experiments performed on Drosophila Me/anogaster have 
in fact shown an  increased incidence of non-disjunction and chromatid breaks (Ahlberg 
et al.,  1972; Ramel,  1973). 
A study made on  human lymphocytes treated in  vitro with trialkyl lead compounds (the 
toxic metabolites of tetra alkyl lead compounds) demonstrated cytogenetic effects, such 
as an  increase in  sister chromatid exchanges (SCE)  and reduced chromosome length, 
at concentrations of the toxic in the culture similar to those found in  blood and tissues of 
exposed subjects (1  J.tmol/1)  (Grandjean and Andersen,  1982). 
On the question of a possible human carcinogenic effect, the negative result of the only 
mortality  study  undertaken  on  workers  exposed  to  TEL  and  observed  for  20  years 9 
(Robinson,  1974 b)  does  not  permit  any definite  conclusions to  be  drawn,  since  the 
population in this study was of a relatively young age (mean age 31.5 years, range 20-58 
years). 
Furthermore, in Robinson's studies (197  4 b,  1976) the mortality and morbidity figures for 
workers exposed to TEL are the same as in  unexposed workers; the author examined 
two groups of subjects employed in the production of TEL for more than 20 years whose 
exposure was "within a range termed 'safe'  by current industrial medicine standards". 
Metabolism 
Absorption 
In  working environments TEL and TEM are easily absorbed via the respiratory tract but, 
due to their high liposolubility they are also easily absorbed via the skin. TEM is absorbed 
less rapidly than TEL via this route (Kehoe,  1983). The digestive system is  not a major 
route of absorption in the working environment. 
Distribution 
In  blood, lead was found predominantly in  the lipid fraction obtained by extraction with 
chloroform-methanol :the mean proportion of lead extracted in blood lipids in three patients 
with TEL poisoning was 73.1 %, which was three times as high as the proportion in blood 
lipids in normal subjects (24%) and in subjects with inorganic lead poisoning (24%) (Beattie 
et al.,  1972). 
The alkyl  compounds are transported from the blood to the liver where they undergo 
metabolic  degradation  by  endoplasmic  reticulum  enzymes  (Cremer,  1959).  A  small 
proportion is also metabolized in the kidney and encephalus, while probably no significant 
metabolization takes place in the blood, spleen and muscles (Bolanowska et al.,  1971). 
Cremer (1959) demonstrated experimentally that TEL is degraded to triethyl lead, diethyl 
lead and metallic lead according to the following  reaction: 
(CH3CH2)4Pb  -+  (CH3CH2bPb +  -+ (CH3CH2bPb + +  -+  Pb + + 
The conversion of TEL to trialkyl compounds is relatively rapid, but conversion to diethyl 
lead and Pb + + is slow. The formation of diethyl lead was not confirmed by Bolanowska 
(1968) in experimental animals, but appears to have been demonstrated in man (Chiesura, 
1970; Yamamura et al.,  1982). 
High quantities of triethyllead concentrate in the brain, reaching much higher levels than 
TEL.  High amounts are also found in  blood and liver. Contrary to inorganic lead triethyl 
lead does not have a particular affinity for the bone tissue. 
The metabolic transformations by TEM  are probably similar to those described for TEL, 
since TEM  is transformed to a trialkyl  compound, i.e.,  trimethyl lead. 
The lower toxicity of TEM compared to TEL appears to be due to slower absorption and 
slower metabolic transformation, with a consequently lower concentration of neurotoxic 
metabolites in  the central  nervous system. 
Excretion 
The degradation products of TEL and TEM  are mainly eliminated with  the urine.  It  has 
also been demonstrated that tetraalkyl compounds can be partially eliminated with expired 
air (Heard et al., 1979). The portion excreted with the feces is mostly due to the high biliary 
excretion of organic lead compounds (Kehoe,  1931 ).  Excretion via the hair, perspiration 
and maternal milk appears to be minimal (Jensen,  1984). 
Biological  Indicators 
The indicators of internal dose (PbB, PbU, PbU-EDTA) and of effect (ALAD, EP,  ALAU, 
CPU)  that  are  commonly  used  for  biological  monitoring  in  occupational  exposure to 
inorganic lead,  behave very differently following exposure to alkyl  lead compounds. 10 
Blood lead levels are generally not significantly high and rarely exceed 50 /Lg/1 00 ml (Muller, 
1953; Kehoe, 1964). In workers exposed daily to low concentrations of TEL or TEM, the 
mean lead concentration in blood was 41-45 /Lg/1 00 ml (De Treville et al.,  1962; Robinson, 
1976). 
In the subjects studied by Kitzmiller et al. (1954) the PbB levels were below 60-70 J.Lg/1 00 ml 
even in the presence of severe intoxication. Lead levels around 400 J.Lg/1 00 ml were found 
in  cases of fatal  human poisoning (Bolanowska et  al.,  1967;  Mizoi  et  al.,  1973). 
In  subjects  exposed  to  alkyl  lead  compounds blood  lead  binds mainly with  the  lipid 
components: the mean  perc~ntage of lead in the lipid fraction of whole blood was about 
three times higher in the subjects exposed to alkyl lead compounds compared to "normal 
subjects" or subjects with  metallic lead poisoning (Beattie et al.,  1972). The correlation 
between severity of symptoms and lipid fraction lead levels seems to be closer than the 
correlation between symptoms and total  blood lead levels. 
In  a study on 5 workers currently exposed to TEL,  no statistically significant correlation 
was found between PbB and atmospheric lead concentrations measured with  personal 
samplers (Cope et al.,  1979). 
In workers moderately exposed to TEL and TEM the mean urinary levels of lead were 90 
to 150 J.Lg/1 with a maximum of 310 J.Lg/1 (De Treville et al., 1962; Robinson, 1974a; Robinson, 
1976). 
Lead excreted with the urine consists essentially of organic lead, mainly diethyllead. This 
finding results from a study made on 6 subjects with acute intoxication who were examined 
at varying intervals (from 3 to 20 days) after accidental exposure to TEL (Chiesura, 1970). 
Determination of lead in urine was made using the method proposed by Bolanowska (1968) 
to differentiate triethyl lead (benzene-extractable), Pb + + ion (precipitable as oxalate) and 
alkyl lead compounds in general (not precipitable as oxalate). Similar results were reported 
in a study by Yamamura et al. (1982) on a worker with acute TEL intoxication. The patient 
was a 48 years old man and urinary lead determinations were done serially between 20 
and 196 days after the exposure and blood lead determination was performed once a 
week. Twenty days after the accident the blood lead level  was 52.3 /Lg/1 00 ml  and the 
urinary lead concentration was 586 /Lg/1. 
In this case determination of the various chemical forms of lead (by atomic absorption after 
specific treatment and extraction) consisted of 50% diethyllead, 480/o inorganic lead and 
about 20/o triethyllead. On the 28th day, total lead consisted of 85% inorganic lead, 10% 
diethyl lead and 5% triethyl  lead (Fig.  1  )  . 
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Fig.  1 Unnary concentrations of tnethyl  lead,  diethyl lead and inorganic lead in  a case of TEL  po1son1ng. 11 
It should be observed, however, that the patient had probably undergone chelation therapy 
on the 4th and 1Oth  day as appears from the graph illustrating this paper. 
A relationship seems to exist between urinary lead levels and appearance of symptoms 
of TEL intoxication. In 49 workers with no clinical signs of intoxication, lead in urine was, 
in  the majority of cases,  below 200  ~-tg/1  and only exceptionally exceeded 300 J.tg/1. 
In 45 subjects with evident symptoms of intoxication PbU was never lower than 200 J.tg/1 
and in  many cases reached much higher levels,  up to 850 J.tg/1  (Faa et al.,  1970). 
Chiesura and Danieli (1969) observed that, when urinary lead exceeds 200 J.tg/1,  there is 
a marked increase in the incidence of gastro-intestinal symptoms (loss of appetite, nausea, 
vomiting,  gastric  complaints,  bad  taste  in  the  mounth)  and  neuropsychic  symptoms 
Table 1.  TEL distillation workers: %  frequency of signs  and symotoms compared to  PbU 
PbU 
ug/1 
N. 
cases 
G.l. (1)  Neuropsychic  CNS (3)  Arterial  (4) 
symptoms  symptoms (2)  alterations  hypotension 
Weigth 
loss (5) 
% 
Pallor 
% 
Diarrhoea 
and/or  No signs 
.  or symptoms 
%  %  %  % 
const1pat1on  011  %  0 
< 110 
110-150 
160-200 
210-250 
260-300 
310-350 
360-400 
410-450 
>450 
34 
152 
211 
251 
90 
57 
25 
17 
15 
7.2 
10.9 
21.1 
24.4 
42.1 
36 
35 
40 
10 
14 
24.3 
31 
38.6 
48 
47 
33.3 
10 
9 
12.3 
28 
30 
32 
35 
10 
6 
4.5 
3.8 
6.7 
16.6 
8.7 
16 
(1)  Lack of appetite,  nausea and vomiting,  gastric trouble,  bad taste  1n  the mouth 
(2)  Asthenia,  headache,  insomnia, troubled  dreams,  dazed state.  dizziness. 
(3)  Tremour,  Romberg test fluctuations,  restlessness,  excitability,  moodiness. 
8.5 
10 
17 
34.4 
36.8 
28 
41 
27 
3 
3.2 
4.2 
7.5 
10 
7 
8 
6 
20 
0.7 
2.3 
4.7 
10 
12.2 
12 
24 
13 
94.1 
71.7 
70 
53 
39 
28 
40 
35 3 
40 
(4)  Systolic pressure reduced by 15-20 mm Hg compared to 7-15 days previously. 
(5)  2-3  Kg weight loss over a relatively short period (about 1 month).  from  Chiesura and Danieli (1969) 
(weakness, headache, insomnia, troubled dreams, dazed state, dizziness) (Table 1). The 
objective signs of intoxication (CNS alterations, weight loss, arterial hypotension) become 
particularly frequent when PbU exceeds 600 J.tg/1,  according to Gherardi and Vidoni (1965). 
On the question of "limit values" for PbU the ACGIH (1963) and Fleming (1964) suggest 
that a PbU level above 110 J.tg/1  should be considered as an indicator of exposure above 
"normal"; when a value of 150 J.tg/1  is registered, the worker must be removed from the 
job. Kehoe (1983) on the other hand, considers that a PbU level of 150 J.tg/1  is indicative 
of "harmful! degree of lead absorption'~; if the PbU values reach 180 J.tg/1, even if the subject 
is  asymptomatic,  he must be moved away from the job involving exposure. 
More recently Grandjean (1984)  raised  doubts as to  whether  a value  of  150 J.tg/1  can 
adequately protect against adverse effects. 
As far  as  the  relationship  between  PbU  and  atmospheric concentrations of  alkyl  lead 
compounds is concerned, Lynch (1975) found that "results from fixed station samplers 
throughout  the  manufacturing  areas  had  not  correlated  well  with  routine  medical 
examinations and urinary excretion levels for lead ...  No correlation could be established 
between  personal  and  fixed  station  monitor  results;  however,  the  mobile  units  gave 
significantly higher values. An approximately linear relationship between breathing zone 
lead levels and urinary excretion was found when the sum of the weekly average organic 
and inorganic  lead  TLV  coefficients  were  related  to  the  corresponding  average  urine 
excretion". 
However, these findings are not of practical importance since the author used, to evaluate 
the environmental exposure, a coefficient obtained with  an  unspecified method. 
Cope at al. (1979) did not find any correlation between atmospehric lead levels and PbU. 
PbU measured after i.v. CaNa2EDTA treatment was altered even some time after cessation 
of exposure to alkyl lead compounds. However, it is not possible with this test to establish 
whether the subject was exposed in the past to alkyl lead compounds or to inorganic lead. 
Administration of 1 g EDTA i.v.  in  45 subjects with  TEL intoxication and base line PbU 
between 40 and 300 J.tg/1 caused a marked increase in urinary lead levels (PbU- EDTA 
=  1407  ±  867 J.tg/24 h)  (Faa et al.,  1970). 12 
In a more recent study made on a subject with acute TEL intoxication after administration 
of 1 g EDTA i.v. a 5-fold increase in urinary inorganic lead levels was observed, whereas 
no significant increase in elimination of diethyl and triethyl lead was seen (Yamamura et 
al.,  1982). 
Administration  of CaNa2EDTA  in  treatment  of TEL  intoxication  may therefore serve to 
accelerate elimination of inorganic lead from the organism, but it apparently does not have 
any effect on the elimination of triethyl and diethyl lead. 
In intoxication by alkyl lead compounds the changes in heme synthesis are less marked 
than might be expected on the basis of the internal dose tests,  especially PbU, probably 
because these compounds are slowly degraded to inorganic lead. 
Miller et al.  (1972) found a reduction in erythrocyte ALAD levels in 27 subjects exposed 
to TEL who had no symptoms of intoxication and who had normal ALAU levels.  In the 
exposed subjects the ALAD levels were about one-third of the levels in the control group. 
The mean PbB  levels were 42.5 ± 10 JLg/1 00 ml  (Table  II). 
Table 2.  ALAD and  PbB  levels  in  subjects exposed to TEL  and  TEM  and  in  a control  group. 
Exposed subjects  Control  group  p* 
n=27  n=9 
ALAD 
nM  PBG/hr/1 010  220±80  677 ±230  <0.001 
red  cells 
PbB ug/1 00  ml  42.5±10  15±5  <0.01 
*  Stat1st1cal  comparison was us1ng  Student's test  for  mdependent samples  from  Millar et  al.  (1972) 
In  a group of 123 asymptomatic subjects exposed to TEL and TEM,  Robinson (1974a) 
demonstrated a significant correlation between ALAU and PbU  (r  =  0.52;  p  <  0.001) 
and a linear type increase in the urinary metabolite.  However, for corresponding levels 
of PbU the ALAU levels in these subjects were definitely lower than in workers exposed 
to inorganic lead (Fig.  2). 
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Fig. 2 Relat1onsh1p  between unnary lead and unnary ALA  1n  organ1c  lead workers (scatter d1agram) and in 
workers exposed to inorganic lead (regress1on  curves). 13 
In subjects with signs and symptoms of moderately severe TEL intoxication Beattie et al. 
(1972) found normal ALAU levels, a slightly increase in EP and CPU and a clear reduction 
in  ALAD. Contrary to the usual  observations these subjects had high PbB levels which 
in  one case exceeded 90 JLg/100 mi.  The  baseline PbU  levels were  between 512 and 
762 JLg/1. 
A study carried out on 13 subjects exposed to TEL for more than 8 years revealed normal 
EP  levels (x  =  21.12 JLg/1 00 ml  ±  2 s.d.  9. 7).  The  PbB levels in the subjects who had 
clinical symptoms of intoxication such as headache and dizziness were between 62 and 
155 JLg/1 00 ml  (X  =  114.2 JLg/1 00 ml)  (Gutniak et  al.,  1964). 
Foa et al.  (1970) found abnormal EP  levels in  subjects who had ceased work involving 
exposure to  alkyl  lead  compounds two  months  before.  The  EP  levels  and  length  of 
employment were significantly correlated and the highest EP levels were found in workers 
with  the longest exposure to TEL. 
Conclusions 
It  is  clear from the above that  PbU  is  the  only biological test that can  be  used for the 
assessment of exposure in  subjects working with  organic lead compounds. 
Various studies have in fact shown that a relationship exists between PbU levels and severity 
of symptoms. In  addition, on the basis of studies reported in the literature,  it seems that 
clinical symptoms appear when PbU  exceeds 200 JLg/1  (Chiesura and Danieli,  1969). 
It does not seem,  however, that the test can be used to assess the degree of exposure 
through inhalation because the levels are not correlated (or only moderately correlated) 
with atmospheric lead concentrations; this could be due to the fact that the substance is 
effectively absorbed through the skin. 
Need  for  Further  Research 
Relationship between PbU  levels and state of health 
Research  should be undertaken on the performance of sensitive neurologic instrument 
tests and  behavioural tests in  subjects with  occupational exposure of varying degrees, 
considering even low levels,  to establish  limit values. 
Research of this type necessitates standardization of the methods of urine collection and 
standardization of the way the  results are expressed. 
Indicators of internal dose 
Further research  should  be undertaken to ascertain: 
- the existence of a possible correlation between lead content of total blood (PbB) and 
the portion of lead bound to the lipid fraction; 
- the existence of a correlation between lead levels in the lipid fraction of the blood and 
symptoms; 
- the existence of a possible correlation of the levels of organic lead in  urine with  PbB 
and with  lead levels in  the lipid fraction; 
- the existence of a possible variation in the PbU  levels during the course of the day, 
so  as to establish the most appropriate time to collect urine samples; 
- the  behaviour  of  PbU  after  cessation  of  exposure  if  possible  in  conjunction  with 
assessment of clinical  symptoms; 
- the relationship between the various chemical forms of lead present in urine (inorganic, 
triethyl and diethyl), so as to assess their behaviour both in currently exposed subjects 
and in  subjects exposed in  the past. 14 
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Dimethylformamide
R. Lauwerys19 
Summary 
DMF vapours are absorbed through the lung and also through the skin. Direct skin contact 
with  DMF solution  represents a frequent circumstance of exposure in  industry. 
DMF exerts its main toxic action on the liver and an early manifestation of excessive uptake 
is  in  the development of alcohol  intolerance. 
N-hydroxymethyi-N-methylformamide (DMF-OH) has been identified as a urinary metabolite 
of DMF. The concentration of N-methylformamide (NMF) in  urine of workers exposed to 
DMF is much less than that of DMF-OH. The latter,  however, is also measured as  NMF 
by gas chromatography along with  the small  proportion of  NMF present in  urine. 
Observations on workers have clearly demonstrated that for a substance like DMF, which 
can enter the organism not only by  inhalation  but also through skin  contact,  biological 
monitoring is  much  better than  ambient monitoring for  assessing  exposure. 
DMF-OH  + NMF  analysis  in  urine  (both  detected  as  a  single  NMF  peak  by  gas 
chromatography) currently appears to  be the best method to  reach this goal.  In  view of 
their short biological  half-life  , it  is  recommended that the urine sample be collected at 
the end of the exposure period. 
No meaningful biological threshold limit value can be proposed as yet but it has been shown 
that a concentration of OMF-OH  + NMF not exceeding 40 to 50 mg/g creatinine in urine 
samples collected at the end of the workshift is  not associated with  signs of acute liver 
damage. 21 
Dimethylformamide 
Introduction 
Chemical and  Physical Properties 
Dimethylformamide  (DMF)  is  a colourless  liquid  at  normal  temperature.  Several  of  its 
chemical and  physical  properties are given in  Table  I. 
Table  1.  Physico-chemical  properties of  dimethylformamide 
Boiling  point (760 mm  Hg):  153°C 
Vapour pressure (25°C): 3.7  mm  Hg 
Water solubility:  infinite 
q 
Formula:  HCN  (CH3)2 
1 ppm:  3 mgfm3 
Effects on  Humans 
The human data on the toxicity of dimethylformamide (DMF) are limited. 
Prolonged skin contact may cause local irritation (Chary,  197  4;  Martelli,  1960; Potter, 1973; 
Rein!  and  Urban,  1965). 
The main target organ following acute or long-term exposure to DMF is the liver (Potter, 
1973; Rein!  and Urban,  1965; To lot et al.,  1968); the gastric mucosa and the pancreas 
may also be affected (Chary, 1974). Nausea, vomiting, abdominal cramps, loss of appetite, 
hepatomegaly and increased activity of various serum  enzymes (GOT,  GPT,  AP,  OCT, 
'Y-GT)  have been  reported in  workers exposed to  DMF for  various periods of time. 
In  man,  an  early  manifestation  of  excessive  exposure  is  the  development  of  alcohol 
intolerance (Chivers, 1978; Lyle et al., 1979). In workers exposed to DMF, various symptoms 
such as  palpitations,  anxiety,  headache, flushing of the face and the trunk,  nausea and 
even vomiting mqy occur when consumption of alcoholic beverages occurs during or within 
a few hours after the end of exposure. 
The available data suggest that,  provided skin contact is prevented, long term exposure 
to an  airborne concentration below 10 ppm will  not lead to the occurrence of biological 
signs of hepatic cytolysis (Krivanek et al.,  1978; Lauwerys et al.,  1980). Nevertheless, at 
this  exposure level  some  individuals may still  present symptoms of  alcohol  intolerance 
(Lauwerys et  al.,  1980; Yonemoto and Suzuki,  1980). 
There is no published human data on the mutagenesis, teratogenesis or carcinogenesis 
of  DMF. 22 
Metabolism 
Human data indicate that DMF absorption occurs not only through inhalation of vapours 
but also by direct skin contact with the liquid form  (Maxfield et  al.,  1975; Kimmerle and 
Eben, 1975b; Lauwerys et al.,  1980). We have found that in workers from an acrylic fibre 
factory skin absorption was more important than inhalation in the overall exposure to the 
solvent when no personal  protective devices were used (Lauwerys et al.,  1980). 
DMF vapour can also be absorbed through contact with skin.  Maxfield et al.  (1975) have 
found  that  when  a  relatively  inactive  man  exposes  a  large  surface  area  to  vapour 
concentrations around 10 ppm for 6 hours, cutaneous absorption may account for one 
quarter to one third of his total metabolite excretion during and for the 24 hours following 
the exposure. 
DMF is rapidly metabolized in vivo. A negligible fraction of the absorbed dose is excreted 
unchanged in urine and in the gastrointestinal tract. Until recently, it was believed that the 
biotransformation  of  DMF  in  vivo,  in  rat,  dog  and  human  consisted  of  a  progressive 
demethylation mediated by the microsomal mixed function oxidases to  yield  N-methyl-
formamide (NMF) and formamide (F) (Kimmerle and Eben, 1975a,b; Krivanek et al.,  1978; 
Lauwerys et al.,  1980; Maxfield et al.,  1975; Scailteur et al.,  1981; Yonemoto and Suzuki, 
1980). 
It has now been demonstrated that the metabolite identified as NMF by gas chromatography 
(Barnes and Henry,  1974) is  mainly N-hydroxymethyi-N-methylformamide (DMF-OH),  a 
stable carbinolamine which breaks down in the injector of the gas chromatograph to give 
NMF (Scailteur et  al.,  1974; Scailteur and  Lauwerys,  1984a,b).  By analogy,  N-hydroxy-
methylformamide (NMF-OH)  is  considered to be the metabolite initially described as  F. 
Only a very small  percentage of the absorbed DMF,  however, is transformed into NMF 
and  F (probably less than 5%). 
The metabolic pathway leading from DMF to DMF-OH involves hydroxyl radicals. The slight 
amount of NMF produced in vivo does not seem to result from further DMF-OH biotrans-
formation but comes directly from DMF (Scailteur and Lauwerys,  1984a,b). NMF is more 
toxic than DMF and the differences between DMF and NMF toxicity were difficult to explain 
when NMF was thought to represent the principal in  vivo metabolite of DMF (Kimmerle 
and Eben, 1975a,b). The metabolic studies (Scailteur et al.,  1984; Scailteur and Lauwerys, 
1984a,b) which demonstrate that following DMF administration, the main urinary metabolite 
is  in  fact  DMF-OH  and  not  NMF,  now  offer  a  logical  explanation  for  these  apparent 
discrepancies, since DMF-OH has been shown to be less acutely toxic than NMF (Scailteur 
and  Lauwerys,  1984b). 
Kimmerle and Eben (1975b) exposed 4 men to 26±8 ppm DMF for 4 hrs and 3 men and 
1 woman to  87 ±25 ppm DMF for 4 hrs. 
Concentrations of DMF and its metabolites (mainly DMF-OH and NMF-OH measured as 
NMF and F respectively) in  blood and  urine were determined. 
DMF was no longer detectable in the blood a few hours after exposure. Only after exposure 
to  87  ppm was  it  detectable in  the urine. 
DMF-OH  (measured  as  NMF)  was  detectable in  the  urine 4  hours after beginning the 
exposure.  The  majority of the substance was  eliminated  within 24  hours. 
The elimination of NMF-OH (measured as  F)  was delayed; it was detectable in  urine up 
to  72  hours after beginning the exposure. 
The same authors also exposed 4 men to 21 ±4 ppm DMF for 4 hrs a day for 5 consecutive 
days.  DMF concentration  in  the  blood decreased rapidly and  generally was  no longer 
detectable 4 hours after the end of exposure. DMF-OH concentration (measured as NMF) 
in  blood during repeated exposure varied from  one person to another but accumulation 
did not occur. Urine analysis also showed that during repeated exposure to approximately 
20 ppm DMF no accumulation of DMF-OH (measured as NMF) occurs in the body. During 
exposure,  DMF-OH  concentration  in  a 24  hours urine sample  remains constant  ( ±30 
mg/24 hr)  but it  was  no  longer detectable 48  hours after the last exposure. 
The authors propose to determine DMF-OH (measured as  NMF) concentration in  24 hr 
urine as a routine monitoring method for employees exposed to DMF. They conclude that 
excretion above 50 mg/24 hr urine indicates exposures exceeding 20 ppm. 
Maxfield  et  al.  (1975)  have  also  exposed  volunteers  to  DMF  (vapours  or  direct  skin 
application) and have measured the rate  of urinary excretion of DMF-OH (measured as 
NMF).  The vapour concentration was  ± 10 ppm and exposure lasted for 6 hours. The 4 
volunteers were dressed  in  shorts,  socks and shoes to  provide nearly maximal  surface 
area for cutaneous absorption. Only skin absorption occurred when a mask was worn but 23 
absorption through both the lungs and skin occurred when no mask was worn. In the case 
of direct skin application, the subjects wore a mask to avoid inhaling vapour and the amount 
of undiluted DMF applied to the skin was 0.3 mi. 
The type of exposure appeared to determine how soon  DMF-OH  (measured  as  NMF) 
appeared in measurable amounts in the urine.  It appeared most promptly when DMF vapour 
was absorbed through both lungs and skin and almost as quickly when DMF liquid was 
applied to the skin,  but later when DMF vapour was absorbed only through the skin.  In 
the first  exposure condition,  the  peak excretion  rate  occurred  within  5  hours after the 
beginning of exposure, whereas in the latter condition, it was not reached before 15 hours. 
Usually,  DMF-OH (measured as  NMF) had disappeared from  the urine on the morning 
after the skin  exposure to liquid DMF and from  samples collected 24 to  26 hours after 
the start of the exposure to DMF vapour, with and without a mask. For exposure to DMF 
vapour at the TLV concentration (30  mg/m3 or 10 ppm),  absorption through the lungs 
accounted for most (61  to 86%) of the total metabolite excreted during the 24 hour interval 
following the exposure. Exposure of large areas of skin to this concentration of DMF vapour 
can,  however,  result in  the absorption of significant amounts of the compound through 
the skin. 
Only a small amount of DMF inhaled or in contact with the skin may be recovered in the 
urine as DMF-OH (measured as NMF). In their experiments, the estimated dose recovered 
ranged from 0.5 to 2%. The authors conclude that the amount of metabolite in  isolated 
urine specimens when collected at a specified time in relation to the work day may serve 
to monitor overexposure to  DMF. 
According to their data, the total amount of DMF-OH (measured as NMF) excreted in the 
urine following 6 hours exposure to 10 ppm DMF is lower than 5 mg. Similar results were 
obtained by Krivanek et al. (1978). They exposed 8 subjects to DMF vapour at an average 
concentration of 8.8 ppm for 6 hrs daily for 5 consecutive days. The amount of DMF-OH 
(measured as NMF) excreted during each 24 hr interval following the beginning of exposure 
amounted to  about 2.5 mg. 
In summary, the volunteer studies indicate that DMF-OH (measured as NMF) appears rapidly 
in the urine of humans exposed to DMF; its biological half-time is short, probably around 
12 hrs.  Unfortunately, the quantitative data obtained by Kimmerle and Eben (1975b) and 
Maxfield et  al.  (Maxfield et al.,  1975;  Krivanek et  al.,  1978) are not in  good agreement 
since the values reported by the latter researchers appear to be about 5 times lower than 
those expected on the basis of the results obtained by Kimmerle and Eben (1975b). 
Factors affecting DMF metabolism 
Eben and Kimmerle (1976) studied the metabolic interaction between DMF and ethanol 
in  rats,  dogs and in  men. 
A delayed biotransformation of DMF was observed in  rats  and dogs when ethanol (2.0 
g/kg) was administered orally prior to acute exposure to DMF vapours (rats: 209, 104 and 
87 ppm for 2 hrs; dogs: 210-240 ppm for 2 hrs). Thus, the DMF concentration in the blood 
was 2 to 6 fold higher in the animals pretreated with ethanol than in control animals. The 
administration  to  rats  of  a lower oral  dose of  ethanol  (0.2  g/kg)  did not  influence the 
metabolism of  DMF. 
During repeated exposure to DMF (200 ppm 2 h/day on 5 consecutive days) and ethanol 
(2.0 g/k p.o.  once a day for 5 consecutive days) the biotransformation of DMF was also 
inhibited.  Furthermore,  they  found  that  in  animals,  the  oxidation  of  ethanol  was  also 
influenced by DMF. 
The authors attempted to confirm the interaction on volunteers. Four persons were exposed 
to 50-80 ppm DMF for 2 hours alone or with previous administration of ethanol (19 g/person). 
A comparatively lower DMF-OH concentration (measured as NMF) in  blood after ethanol 
administration indicates that ethanol can also influence the metabolism of  DMF in  man. 
The comparison of the ethanol and acetaldehyde concentration in the blood after ethanol 
administration with or without exposure to DMF (82 ± 20 ppm for 2 hrs) did not produce 
definite results  since in  both conditions acetaldehyde was  not detected in  the  blood. 
We  have,  however,  indicated  above that  an  antabuse-like effect of  DMF  is  a frequent 
observation in workers exposed to this solvent. This may be due to an inhibition of alcohol 
deshydrogenase by DMF (Sharkawi,  1979). 24 
Biological  Indicators 
Several biological parameters can be considered for the evaluation of exposure to dimethyl-
formamide. 
DMF  in  blood 
DMF  in  expired air 
- The sum of N-hydroxymethyl- N-methylformamide (DMF-OH) and N-methylformamide 
(NFM)  in  blood.  Both  metabolites are  measured as  NMF by gas chromatography. 
- The  sum  of  DMF-OH  and  NMF in  urine.  Both  metabolites are measured as  NMF. 
- The sum  of  N-hydroxymethylformamide (NMF-OH) and formamide (F)  in  urine.  Both 
metabolites are  measured as  F. 
DMF in  blood 
DMF can be measured in  blood (Kimmerle and Eben,  1975a).  From  data published by 
Kimmerle  and  Eben  (1975b)  it  appears  that  DMF  concentration  in  blood  increases 
continuously during exposure and  disappears rapidly after the end of exposure. 
At the end of a 4-hour exposure to average atmospheric concentrations of 21  and 87 ppm, 
the  mean  DMF  concentration  in  blood  amounted  to  about  0.3  and  1.4  mg/1 00 ml 
respectively. 
The time of sampling is very critical, which limited the usefulness of the test for the routine 
control  of workers. 
DMF in  expired air 
When  skin  contact with  DMF can  be  prevented, there is  during exposure a significant 
correlation  between  environmental  exposure  and  DMF  concentration  in  alveolar  air. 
According to  Brugnone et al.  (1980), the alveolar concentration amounts on  average to 
3 mg/m3 when the atmospheric concentration of  DMF is  10 mg/m3. 
Sum of DMF-OH  and  NMF  in  blood 
As indicated above, DMF-OH represents the main oxidative metabolite of DMF, NMF being 
a  minor  metabolite.  The  gas  chromatographic  method  initially  developed  for  NMF 
determination, measures both  NMF and  DMF-OH  which is demethylated to  NMF in the 
injector of the gas chromatograph. 
Unlike DMF,  the level  of  DMF-OH  in  blood (measured as  NMF) seems to  remain  fairly 
constant for  a few hours after the end of exposure (Kimmerle and Eben,  1975b). 
The only data available relating DMF-OH ( + NMF) concentration in  blood and exposure 
to DMF are those of Kimmerle and Eben (1975b) based on 4 volunteers exposed to DMF 
vapours at concentrations ranging from 21  to 87 ppm. At the end of the exposure, DMF-
OH ( + NMF) in blood amounted on the average to 0.2 mg/1 00 ml (21  ppm) and 0.6 mg/1 
(87  ppm). 
More data on humans are required to evaluate the relationship of this parameter with the 
intensity of exposure. 
Sum  of DMF-OH and  NMF in  urine 
In workers exposed to DMF,  DMF-OH constitutes the main urinary metabolite; only a trace 
amount of NMF is  present in  urine.  However, the gas chromatographic technique used 
for  urine  analysis  cannot  distinguish  between  both  metabolites  since  DMF-OH  is 
demethylated to  NMF at  high temperature (see  above). 
Data available from both human volunteers and workers exposed have demonstrated that 
DMF-OH ( + NMF) analysis in urine is useful for monitoring exposure to DMF.  However, 
the results permitting to relate exposure to DMF,  and amount of metabolites (DMF-OH  + 
NMF) excreted are  still  very limited. 
Furthermore, the results of Maxfield et al. (1975) indicate that individual variation in metabolite 
excretion is high,  probably resulting from  differences in the actual amount absorbed as 
well  as factors such  as the  rate  of  metabolism and/or renal  clearance. 
We  have already indicated that according to  Maxfield et  al.  (1975) data based only on 
4 volunteers, the total amount of DMF-OH  +  NMF excreted in the urine following a 6-hour 
exposure to 10 ppm DMF vapour is on the average less than 5 mg (range 2 to 5.75 mg). 25 
The results obtained by Kimmerle and Eben (1975b) on 4 volunteers are summarized in 
Table  II. 
Table 2.  Urinary excretion  of  DMF-OH  plus  NMF  1n  4 volunteers exposed to  DMF  vapour. 
mg  DMF-OH + NMF excreted within  24  hours after 
Exposure  beginning  of  exposure 
Subject  1  Subject 2  Subject 3  Subject 4 
26  ppm  4 hr  26  21  27  22 
87  ppm  4 hr  94  90  111  95 
21  ppm  4 hr  on  the average 25  to  30 mg  per each 
(5  consecutive days)  24  hr  period  (4  subjects) 
Catenacci et  al.  (1980) Yonemoto and Suzuki  (1980) and Wicarowa and  Oadah  (1980) 
examined workers exposed to dimethylformamide and found a relationship between the 
environmental  concentration  of the  solvent  and the amount of  DMF-OH  + NMF (both 
measured as  NMF)  excreted  in  24  hours.  Their  quantitative results,  however,  are  very 
different since, for an exposure to 10 ppm DMF, the first group of authors found an excretion 
of 12- 15 mg DMF-OH  + NMF per 24 hours, whereas Yonemoto and Suzuki (1980) and 
Wicarova and Dadah (1981)  reported an  average excretion of 5 and 6 mg of OMF-OH 
+  NMF per 24  hours,  respectively,  for the same exposure level. 
Differences in the percutaneous absorption of DMF and  in  alcohol consumption,  which 
interferes with  DMF metabolism,  might explain this discrepancy. 
Lauwerys et al. (1980) have carried out a field study in an acrylic fibre factory. DMF vapour 
concentration was measured at different workplaces with static samplers during a week 
and the  time  spent  by  each  worker  at  different  places  during each  working  day was 
estimated.  For  each  worker and for  each  day an  integrated exposure (concentration x 
duration) was calculated. It should, however, be recognized that during some operations, 
skin contact also occurred and that the airborne concentration did not necessarily reflect 
the total  exposure.  Urine samples were collected immediately before and after the shift 
for  5 or 6 consecutive days. 
Several  observations previously made on  volunteers were confirmed: 
1.  The sum of DMF-OH  + NMF (both measured as NMF) in urine is a sensitive biological 
parameter of exposure. The  presence of  metabolites (mainly DMF-OH)  in  urine can 
be easily detected even when the average airborne DMF concentration is  below 30 
mg/m3, the current ACGIH  TLV  (integrated exposure:  180 mg.h.m-3). 
2.  The metabolism of absorbed DMF is  rather rapid:  DMF-OH  +  NMF concentration in 
urine is  usually greater at the end of the shift than  in  the morning of the  next day. 
3.  In a group of workers the sum of DMF-OH  + NMF in urine at the end of the shift seems 
to  reflect the  intensity of exposure of the same day. 
On  an  individual  basis (N  =  116) there was a very low correlation  between integrated 
exposure and  DMF-OH  +  NMF concentration  (expressed  in  mg/g creatinine)  in  urine 
collected at the end of the shift (r  =  0.24 P < 0.01 0) or before (r  =  0.16 P > 0.05) resuming 
work the  next day (i.e.  ± 16 hours after the end of the work). 
This could be due to individual variation in metabolism (mainly rate of excretion) but also 
to an error in the estimation of the total exposure since we know that in this type of industry 
skin  contact  with  DMF  solution  is  an  important  route  of  absorption.  This  was  clearly 
demonstrated by comparing the urinary excretion of  DMF-OH  +  NMF (both  measured 
as  NMF by gas chromatography) in  workers using different protective devices (Fig.  1  ). 
The metabolite concentration in urine collected at the end of a day when the workers were 
equipped with a self-contained breathing apparatus but did not protect their skin (i.e. first 
day of week 3,  in  Fig.  1) was about three times higher than during the period when only 
their skin  was  protected with  gloves (Fig.  1  ). 
The results of the health screening of these workers also suggested that a concentration 
of DMF-OH  + NMF (both measured as  NMF by gas chromatography) in  urine samples 
collected at the end of the workshift not exceeding 40 to 50 mg/g creatinine is not associated 
with  signs of acute liver damage (Lauwerys et al.,  1980). Such exposure, however, may 
still  be associated with  signs of alcohol intolerance. These results also demonstrate very 
clearly that for a substance like DMF, which can enter the organism not only by inhalation 
but also through skin contact, biological monitoring is much better than amb1ent monitoring 
in  assessing  exposure. 26 
Dixon et al.  (1983) have noted a seasonal variation in the urinary concentration of DMF-
OH  +  NMF (both  measured  as  NMF)  in  workers  exposed to  DMF.  This  change was 
attributed to seasonal differences in  urine volume. Twenty-four hour urine volumes were 
on  the average 13% lower in  hot weather than  in  cold weather. 
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Fig. 1 Urinary excret1on  of DMF-OH  +  NMF (both measured as NMF by gas chromatography) in  workers 
using different protect1ve  dev1ces. 
Sum of NMF-OH and  F in  urine 
The experiments on volunteers exposed to DMF vapours (Kimmerle and Eben,  1975b) 
suggest that the excretion of NMF-OH  + F (measured as F)  in urine is dose-dependent. 
However, the excretion of NMF-OH  + F is slightly delayed. The highest concentration was 
found  between 4 and 20 hours after the end of the test.  As  indicated above,  however, 
the concentration of NMF-OH  +  F is  also  lower than that of  DMF-OH  +  NMF. 
Conclusion 
Since in industrial settings the skin represents an important, if not the major route of DMF 
entry into the organism, the possibility of assessing exposure to this solvent by a biological 
method is  obvious.  It  represents the only approach to estimating the total  uptake. 
Among the  biological tests  which  have been  considered for  evaluating the intensity of 
exposure to DMF, the determination of DMF-OH  + NMF {both measured as NMF by gas 
chromatography) in  urine appears to  be  the most practical. 27 
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Summary 
The characteristics of the metabolism and toxicology of mercury vapours and inorganic 
compounds are substantially different compared with organic compounds. Metallic mercury 
is widely  used  in  industry.  In  chronic exposure the  main  alterations involve the central 
nervous system. The main route of absorption in occupational exposure is via the respiratory 
apparatus.  Mercury easily passes the  blood-brain barrier and  accumulates in the brain. 
Mercury is mainly eliminated with the urine. Determination of mercury in urine is at present 
the most widely used indicator of exposure; values calculated on a group basis were found 
to be well correlated with the environmental concentrations.  However, the correlations can 
be established only after about one year from the beginning of exposure, when the binding 
sites in the kidney are saturated.  It should be borne in mind that although HgU is an indicator 
of exposure, it does not permit evaluation of the dose in the critical organ (central nervous 
system). Fewer studies have been made on the behaviour of HgB.  It has been found that 
the levels of this indicator are correlated with the levels of HgU in occupationally exposed 
subjects.  At present no  biological tests are available that can  be  used for  evaluation  of 
early  reversible effects due to  mercury. 
Due to the high toxicity of organic mercury compounds, especially alkyl mercurials, their 
use in industry has been banned in many countries. Non-occupational exposure to these 
compounds, via ingestion of contaminated food, does, however, occur to a considerable 
extent.  The digestive apparatus is the most effective route of absorption and elimination 
occurs via the faeces.  Organic mercury compounds easily cross the blood-brain barrier 
causing serious alterations to the central nervous system. The measurement of HgB is a 
useful test for evaluating the degree of exposure, but measurement of HgU is of no practical 
use.  No indicators of early  biological  effect exist for alkyl  mercury compounds. 33 
Mercury 
Introduction 
Physico-chemical Properties 
Mercury exists in nature in liquid state at ambient temperature. Atomic weight: 200.6, atomic 
number: 81,  density : 13.6, melting  point: -38.9°C.  Oxidation state  is  + 1 and  + 2. 
Mercury vapours are considered to be insoluble in  water;  solubility in liquids at ordinary 
temperatures is  in  the order of 5-50 mg/1. 
Mercury salts  such  as  alides,  sulphates  and  nitrates  are  soluble  in  water.  Mercury is 
contained in the earth's crust mainly in the form of a sulphide; the red sulphide or cinnabar 
is the ore richest in  mercury, containing up to 700/o  (Berlin,  1979). 
Mercury is capable of forming organic compounds such as alkyl-, phenyl- and methoxylalkyl 
mercurials. However, the distinction between organic and inorganic compounds has more 
of a didactic or chemical value than a toxicological basis.  Within these two groups, for 
example, the toxic properties of elemental mercury vapours differ from those of inorganic 
mercury salts;  moreover, the adverse effects of the alkyl mercurials have been shown to 
differ dramatically from the other organic mercury compounds. 
The industrial consumption of mercury, which amounted to less than 8000 tons/year in 
1980,  appears to  be  slowly  but constantly  declining.  Consumption  of  mercury  in  the 
European Common Market was 1164 tons in  1982. Distribution in the various industrial 
sectors in the period 1977-78 was: over 600/o in the chemical industry (chlor-alkalis, paints), 
12% in  the  accumulator  industry,  70fo  in  the  precision  instruments  industry,  and  the 
remaining 20% in  miscellaneous uses (Fig.  1)  (Eurostat,  1979-82) 
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Fig.  1 Consumption of  mercury 1n  EEC countnes and d1stnbut1on  1n  vanous 1ndustnal  sectors 
(From  Eurostat.  1979-82) 
Organic mercury compounds such as the methylmercurials and ethylmercurials are widely 
used in agriculture as fungicides; however, the majority of the industrialized countries have 
banned their use (Berlin,  1979). 34 
Effects on  Humans 
Acute occupational intoxication by metallic mercury is  rather rare and occurs following 
inhalation  of  large  quantities  of  the  vapours.  The  effects  are  seen  on  the  respiratory 
apparatus, varying from slight bronchial irritation to pulmonary oedema leading to fibrosis 
(Browning,  1969;  Hamilton and  Hardy,  197  4;  Seaton and Bishop,  1978;  Berlin,  1979). 
Rare cases of "mercurial pneumonia" have been described even following exposure to 
environmental mercury concentrations between 1 and 3 mg/m
3 (Friberg and Nordberg, 
1972). 
In chronic occupational intoxication the target organ is the central nervous system. The 
pronounced clinical symptoms are characterized mainly by tremour and psychic erethism us. 
Static and intentional tremour, with serious emotional aggravation is initially slight and hardly 
noticeable, involving only the face;  it becomes progressively more evident, involving the 
limbs, and can hinder normal activities such as eating, dressing and walking. There are 
evident changes in handwriting and speech monotonous, syllabized, stammering (Hamilton 
and  Hardy,  1974;  Baldi,  Vigliani  and  Zurlo,  1953;  Foa,  1977;  Berlin,  1979).  Psychic 
erethismus has been described as irritability, changes in sociableness, anxiety, insecurity, 
loss of memory (Hamilton and Hardy,  1974; Berlin,  1979). Sometimes these symptoms 
are the only signs of early mercury poisoning so that some authors have used the term 
micromercurialism (Berlin,  1979). 
Cases of polyneuritis have been described in workers with mercury intoxication. In addition 
to significant electroneurographic evidence of motor conduction velocity impairment in 
workers, clinical findings indicating alterations of both sensory and motor nerve fibres have 
been reported. These findings have been explained as the result of the toxic effect of mercury 
on the anterior horn motor neurons with axonal degeneration (Vroom and Greer,  1972; 
Gilioli  et al.,  1976;  Levine et a1.,.1982). 
The central  nervous system  is  seriously involved  particularly in  intoxication  by organic 
compounds, giving rise to sensory and motor nerve effects (leading even to generalized 
ataxy), sight defects with concentrical restriction of the visual field and, in the most serious 
cases, blindness, deafness, drowsiness and coma (AI-Damluji, 1976; Skerfving and Vostal, 
1972). Involvement of the peripheral nervous system has also been described (Skerfving 
and Copplestone, 1976). In ethylmercury poisoning the damaging effects on the kidney 
are of a peculiar and specific nature (AI-Damluji,  1976). 
Serious outbreaks of collective methylmercury intoxication occurred in Minamata and Niigata 
in Japan (700 cases) and Iraq (1600 cases) following ingestion of contaminated fish  and 
cereals. 
Mutagenesis 
An increased frequency of aneuploid cells was observed in the lymphocytes of workers 
exposed to mercury vapours (Verschaeve et al.,  1976). The same authors also observed 
chromosomal aberrations in workers exposed to ethylmercury. Skerfving et al. (197  4) found 
chromosomal aberrations in the lymphocytes of subjects who had eaten fish contaminated 
with  methylmercury proportionate in  number to the dose ingested. 
Other authors did not find an increased incidence of chromosomal aberrations in subjects 
suffering  from  accidental  methylmercury poisoning,  compared to  a control  population 
(Baghdad Meeting,  1974). 
An increased incidence of chromosomal aberrations not accompanied by any significant 
variations in frequency of aneuploid or polyploid cells or sister chromatid exchanges was 
found both in workers exposed to metallic mercury and in workers exposed to a mixture 
of methylmercury and ehtylmercury (Popescu et al.,  1979). 
Metabolism 
Absorption,  distribution  and  excretion  of  mercury  vary  considerably  according to  the 
chemical form  it takes. 
Absorption 
Metallic mercury (Hg
0
)  is  the form  most widely encountered in  occupational exposure. 
Mercury vapours and dusts or aerosols of inorganic mercury are absorbed via the respiratory 
tract in amounts or at sites depending upon their particle size and solubility in biological fluids. 
Absorption by the inhalation route is a highly efficient process. In fact, the affinity of mercury 
for proteins and all other substances with a sulphydryl group explains the capacity of the 35 
metal for immediate reaction with the active groups of the respiratory mucosa, which has 
a surplus of sulphydryl groups, compared with the relatively small  quantities of mercury 
inhaled. Equilibrium between Hg in air and in plasma is reached within a very short time 
from the beginning of exposure, and 20 hours after cessation of exposure the lung contains 
practically no  more of the metal. 
The  percentage  of  lung  retention  following  a  single  exposure  (subjects  exposed  to 
concentrations of 100 11-g/m
3 of labelled mercury) varies from 7  4 to 76% when inspiration 
is through the nose,  to 5QO/o  when  inspiration and expiration is through the mouth;  the 
retention percentage remains constant in time even if exposure continues (Hursh et al., 
1976;  Teisinger and  Fiserova Bergorova,  1965). 
In  occupational  exposure,  absorption  by  ingestion  can  be  considered  as  accidental. 
Nevertheless, if the vapours inhaled are at a higher temperature than the body temperature, 
they may condense on  the mucosa of the mouth and upper respiratory tract and then 
be swallowed.  If  elemental  mercury is  ingested,  however, the oxidation  process in  the 
intestinal tract is usually too slow to be completed before the mercury is eliminated with 
the faeces (Clarkson,  1972,  I and II).  Inorganic mercury and its salts are absorbed very 
slightly by the  intestinal  tract;  the  portion absorbed is  calculated as  being  20/o  to  1  0% 
(Clarkson,  1971;  Rahola et  al.,  1973). 
If conveyed by organic solvents,  the inorganic compounds could  be  absorbed via the 
undamaged skin,  where part of the mercury could be converted to elemental  mercury 
and there deposited. 
Organic compounds, however, are easily absorbed via the intestines: between 50% and 
800/o  of the ingested doses,  with  peaks up to 94-950/o  in  the case of methylmercury,  is 
absorbed by this route. 
Distribution 
The distribution of mercury in the body tends to establish a state of equilibrium determined 
by  the  following  factors:  concentration  of  mercury  compounds  in  the  various  blood 
compartments;  related  concentrations of  free  sulphydryl  groups;  affinity  of the cellular 
components for mercury; velocity of association and dissociation of the mercury-protein 
complex.  Ninety-five percent of the sulphydryl group of the blood are found  in  the red 
blood cells:  9QO/o in the globin, 4% in the membrane, and the remainder in the reduced 
glutathione; the albumin in the  plasma has the largest supply of sulphydryl groups. 
If the mercury compounds were equally distributed among the sulphydryl groups of the 
blood, the highest portion should be bound to the red blood cells. However, considerable 
differences are recorded among the different mercury compounds and among different 
animal  species,  just  as  distribution also varies  among  the  different blood components 
according to the dose and length of exposure. 
Generally speaking, however, it can be said that, while 900/o of the organic compounds 
are transported inside the red  blood cells, about 50% or more of inorganic mercury 
is transported into the plasma, especially bound to the albumin. 
Also, the distribution of mercury in the various compartments of the body depends on the 
dose, length of exposure, degree of oxidation of mercury, and the type of compound to 
which  mercury is  bound (Brown and  Kulkarni,  1967). 
When mercury vapours are inhaled, oxidation of elemental mercury is completed partly 
in the blood, mostly in the erythrocytes (Clarkson, 1979) and partly in the tissues by means 
of a catalase (Nielsen-Kudsk,  1971;  Magos,  197  4).  However,  alongside the  portion of 
mercury present in oxidised form, there is a portion in the blood in a not yet ionized state 
(Magos, 1967, 1968). The diffusion of the latter portion from the blood into the tissues and 
through the cell  membranes is facilitated  by its greater liposolubility and by the lack of 
any electrical charge,  allowing it to pass the  blood-brain barrier. 
Consequently, the levels of mercury in the brain are 10 times higher following exposure 
to vapours of elemental mercury compared with administration of identical quantities 
of ionized mercury in  various animal species (Berlin  et  al.,  1966;  Berlin et al.,  1969). 
After absorption, elemental mercury, oxidized into mercury ion,  behaves toxicologically 
like that ion (Friberg and Nordberg,  1972;  Friberg and Vestal,  1972). 
A study of the distribution of elemental mercury in the central nervous system in rats and 
mice (Cassano et al.,  1966) revealed a greater mercury concentration in the grey matter 
than in the white, with the highest levels in certain neurones of the cerebellum, of the spinal 
cord, medulla, pons and mid-brain.  In the cerebellum, a selective localization was noted 
in  the  Purkinje cells and  in  the neurones of the dentate nucleus. 
Available data from long-term exposure of squirrel monkeys (Berlin, 1979) and a few clinical 
cases  of  occupational  exposure (Takahata et  al.,  1970; Watanabe,  1971) indicate that 36 
mercury is accumulated in the cerebral cortex, especially in the occipital and parietal cortical 
areas. 
In other organs, the distribution of elemental mercury is identical to the distribution of mercury 
ion,  with  high concentrations in the kidney and the liver,  in the intestinal mucosa and in 
the testicles (Berlin,  1979). 
Mercury ion is very rapidly distributed in  the tissues where it is found a few hours after 
exposure.  It accumulates in the kidneys,  in the liver,  in the myocardium, in the mucosa 
of the intestines,  of the upper airways,  of the mouth and especially of the  nose,  in  the 
interstitial tissues of the testicles,  in  the skin,  in  the  bone marrow and in  the  placenta. 
Accumulation is most marked in the kidney: the quantity of mercury in the renal cortex 
already exceeds the quantity in  the blood one hour after administration. The  biological 
half-life of inorganic mercury accumulated in the kidney,  which  has been calculated as 
64 days (Miettinen, 1971; Katzantzis et al.,  1976), is longer than in the whole body (58 days) 
(Hursh et  al.,  1976),  but in  any case shorter than in  the central nervous system,  where 
it is  as  much as a year (Berlin and Hulberg,  1966,  I and  II;  Takahata et  al.,  1970),  but 
where the uptake is,  however,  much slower. 
There are, however, considerable differences between organic mercury compounds and 
inorganic mercury salts as far as the respective concentrations in the CNS are concerned, 
even if the type of distribution has been confirmed to be the same on the basis of studies 
of autopsy material from subjects who died following mercury intoxication in Minamata 
(Brown and Kulkarni,  1967;  Davis et  al.,  1974; Takahata et  al.,  1970). 
The  alkyl  compounds  cross  the  blood-brain  barrier  more  easily  than  the  inorganic 
compounds (Cassitto and Gilioli,  1980). 
Further,  among the  same  organic compounds,  considerable differences in  velocity of 
removal from tissues and in  brain concentrations are found between alkyl and aryl salts. 
Phenyl  mercury,  for  example,  is  less  rapidly  metabolized  to  inorganic  mercury than 
methoxyethyl mercury (Daniel  et  al.,  1971; Gage,  1975). 
Among the alkyl salts, methyl mercury is much more easily transported across the placental 
barrier, reaching concentrations in the foetal red blood cells 30% higher than those of the 
mother. All mercury compounds can be directly or indirectly converted to methyl mercury 
in the body.  Although such conversions are only seen experimentally,  nevertheless the 
finding of increased organic mercury levels in the urine, in concomitance with an increased 
exposure in  subjects exposed to mercury vapours,  shows that this may also happen in 
the human body (Suzuki  and Shishido,  1971). 
On the other hand, the possibility of a biotransformation of methyl mercury compounds, 
with  liberation of inorganic mercury,  has been demonstrated in  several  animal  species 
(Nordberg and Skerfving,  1971) and also in  humans (Sumino,  1978; Bakir et al.,  1973). 
Since  it  has  been  established that  absorption  by the  intestinal  route  is  1  ooo/o,  and  by 
evaluating the biological half-life at 70 days, the theoretical accumulation curve of methyl 
mercury in  humans can be calculated for various doses of methyl mercury (Kitamura et 
al.,  1976). 
Excretion 
Inorganic mercury, by whichever route it has been absorbed, is mainly excreted via the 
kidneys. A minor degree of excretion occurs through the bile, the intestinal mucosa, the 
sudorific and salivary glands,  the  hair and  nails,  the faeces,  and via the skin  both  by 
volatilization and desquamation (Swensson et al.,  1959; Weed et al.,  1962; Berlin, 1963; 
Magos,  1968).  The  kidney acts  as  a  multicompartmental  model  in  which  at  least  one 
compartment is characterized by a high retention time (Miettinen, 1971 ). However, the exact 
mechanism of mercury uptake by the plasma and its subsequent release in the tubules 
are not clear, although experimental research suggests that mercury might be secreted 
from the kidney tubules. Similarly it has not been established whether the excretion and 
reabsorption sites are the same, with different pH  or mercury concentration gradients, or 
separate (e.g. excretion through the proximal tubule, reabsorption through the distal tubule). 
In any case, it is certain that two processes, excretion and deposition, through the kidney 
parenchyma,  do not proceed in  a synchronized manner. 
From the onset of exposure there  is a latency period  in  maximum  excretion  until  the 
kidney  has  accumulated  a certain  quantity. 
In  intermittent exposures (as  is the case in  many occupational exposures), this latency 
mechanism can give rise to the appearance of an  excretion peak during period of non-
exposure. 
The persistence of urinary elimination of mercury even for a considerable period of time 
after cessation of exposure could warrant the supposition that the metal is incorporated 
irreversibly into the  protein cells,  after which the excretion frequency would depend on 
the metabolic turnover of the proteins (Vostal  and Heller,  1968). 37 
Comparing  kidney accumulation  and excretion,  quantitative differences can  be noted 
according  to  the  various  compounds.  With  inorganic  mercury,  50%  of  the  dose  is 
accumulated in the kidney, less than 10% is excreted, while only 1  0% of methyl mercury 
is accumulated in the kidney with an excretion rate 10 times lower than inorganic mercury. 
About 90°/o of organic mercury is excreted by the fecal  route (Berlin,  1979). Also,  a fair 
portion of mercury is eliminated with  perspiration.  Even though this route of elimination 
has not been the subject of much study,  it  should be noted how in 3 workes at a chlor-
alkali plant (Lovejoy et al.,  1973) the concentrations of mercury found in the sweat were 
between 50 and 2000/o higher than those in the urine. This finding assumes importance 
if it is considered that high temperatures (with consequent excessive sweating) are frequent 
in  chlor-alkali plants,  which are not built in  the open. 
Biological  Monitoring 
In  view of their  different meanings,  the  biological  indicators for  inorganic and organic 
compounds will  be dealt with  in  separate chapters. 
Inorganic Compounds 
Indicators of internal  dose 
Mercury in  urine 
The mean levels of mercury in urine in non-exposed populations resulting from the latest 
studies were below 1  0  ~-tg/1 even though with  rather wide ranges (from 0 to 42  ~-tg/1) and 
with variations influenced by the area of residence (Kubasik et al.,  1972; Cigna Rossi et 
al.,  1976; Stopford et al.,  1978; Lie et al.,  1982). In occupationally exposed subjects, the 
urinary mercury levels showed rather conspicuous per cent variations,  both from day to 
day and  during  the  same  day,  even  though  the  exposure  conditions  were  constant 
(Goldwater et al.,  1963;  Piotrowsky et al.,  1975). 
It was, however, found that the intraindividual variations can be reduced by collecting the 
urine samples at the same time in  the morning (Piotrowsky,  1975). 
However, according to Stopford et al.  (1978), urinary mercury at the end of the working 
week is as indicative of mean exposure to mercury vapours in that week as the mean of 
the urinary mercury values in  samples collected over the entire week. 
After removal of subjects from exposure, two phases of urinary excretion of mercury were 
identified :the first phase lasts on average 2 days and accounts for not more than 20-30% 
of excretion in  steady state;  the second phase has a half-life of 70 days (Piotrowsky et 
al.,  1975). This confirms the experimental data obtained in  human subjects with marked 
mercury, showing that mercury has a half-life of 64 days in  the kidney (Cherian,  1978) 
and is indicative of the tendency of mercury to accumulate in the kidney until steady state 
is reached, i.e.  saturation of the binding sites in the tissue (metallothioneine). In a subject 
exposed  to  constant  environmental  mercury  concentrations,  this  state  is  reached  in 
approximately one year;  before this time, the urinary mercury values are thought to be 
more indicative of the quantity of metal deposited in the kidney rather than of the current 
environmental exposure levels (Stopford, 1978). This explains why in intermittent exposures 
(as is the case in many occupational exposures) high urinary excretions can occur during 
a period of non-exposure. 
The persistence of urinary elimination of mercury, even. for a considerable period of time 
after cessation  of exposure,  has also  been  explained  by a  mechanism  of  irreversible 
incorporation of the metal into the cellular proteins of the kidney; the persistence of mercury 
excretion is believed to depend on the metabolic turnover of the proteins (Vostal and Heller, 
1968). 
There is rather unanimous agreement among the various studies that the urinary mercury 
levels,  when  mean  group values  are  considered,  are  well  correlated  with  the  mean 
atmospheric concentrations of mercury at the workplace. In workers of a chlor-alkali plant, 
Smith et al. (1968) found urinary group values between 100 and 300  ~-tg/1 for environmental 
mercury concentrations of 0.1  mg/m
3
;  the urinary values fell  by 50% at  environmental 
concentrations of 0.05 mg/m
3
. In a later study, the same author established a ratio of 1.25 
between urinary and environmental mercury on a group basis (Fig.  2) 38 
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Fig.  2 Relationship between mean mercury concentrations in  air and mean values of HgU in  groups of chlor-
alkali workers. 
(From Smith  et al.,  1970) 
Lauwerys et al. (1973), again for group values, suggested that for exposures to 0.05 mg/m
3 
(ACGIH-TLV), the urinary values are about 50 J.tg/1  rather than 100 J.tg/1.  A  1/1  ratio was 
found in other studies (Bell,  1973; Nakaaki, 1975; Stopford et al.,  1978; Gambini, 1978) 
(Fig.  3).  The WHO Study Group (1979) accepted a ratio of 1/2 as more likely. 
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Fig. 3 Relationship between mean concentrations of  mercury 1n  a1r  and mean values of HgU  in  groups of 
chlor-alkali workers. 
(From  Gamb1ni,  1978) 
The possibility that a correlation between individual urinary mercury levels and environmental 
mercury levels could exist was revealed by the studies of Bell (1973) and Stopford et al. 
(1978), who assigned greater importance to the microenvironment (contamination of hands 
and clothing) as a significant source of mercury vapours. In particular, Stopford et al. (1978), 
using  personal  samplers,  found  a  close  correlation  between  urinary  mercury  and 
atmospheric mercury present in the microenvironment, while only a moderate correlation 
was found between urinary mercury and atmospheric mercury concentrations in the macro-
environment. 39 
Gambini (1978) did not find any significant increase in psychic erethismus and tremor in 
exposed subjects when urinary mercury values were below 50 ~tgll. The WHO tentatively 
proposed 50  ~tgll as a limit value since,  on the basis of a 1/1  ratio,  this corresponds to 
an  atmospheric value of 0.05 mg/m
3
, which is the ACGIH's TLV-TWA value (1984). The 
WHO changed this value to 50  ~tglg creatinine in  1985 (individual  level). 
Landolt  et  al.  (1978)  did  not  find  any  alterations  in  psychometric  tests  or  tremour 
measurement tests in exposed subjects whose urinary mercury values had not exceeded 
50  ~tgll  in  the previous year. 
An increased frequency of abnormalities in psychometric tests and tremometry was found 
when urinary mercury values were between 50 and 100 ~tglg creatinine (Roels et al.,  1982). 
At  these values there was also  an  increased frequency of proteinuria and albuminuria 
compared to a control group (Buchet,  1980; Roels,  1982). 
It should, however, be emphasized that even if HgU can be considered as an exposure 
indicator, it cannot be used to assess the dose in the critical organ, i.e. the brain, because 
the average life of mercury deposited in  the brain is  much longer than  in  other organs 
and therefore high quantities can remain  in the brain  after cessation of exposure. 
Mercury in total blood 
In the most studies on populations consuming moderate or negligible quantities of fish, 
the mean values of mercury in blood in non-occupationally exposed subjects were below 
3  ~tg/100 ml,  with  a range from 0.03 to 10  ~tg/100 ml  (Paccagnella et al.,  1973; Turner, 
1974; Den Tonkelar, 1974; Cigna Rossi et al.,  1976; Bourcier et al.,  1982). Few data are 
available on blood mercury levels in exposed subjects. Smith  et al.  (1970) found values 
below 5  ~tg/1 00 ml  over a total  of  117 individuals. 
Lauwerys et al.  (1973)  found  mean values of 0.65 ±0.11  ~tg/1 00 ml  over a total  of 23 
subjects, whereas Roels et al.  (1982) found mean values of 0.23 ~tg/1 00 ml with a range 
of 0.05 - 0.59 over a total  of 47  individuals. 
Significant correlations between blood mercury levels and atmospheric mercury were found 
by Smith  et al.  (1970)  on  a group value  basis. 
Stopford et al.  (1978) found a significant correlation between blood mercury values and 
mean values of microenvironmental exposure measured on the previous five  days,  but 
not with the microenvironmental exposure values measured on the day blood samples 
were taken for HgB assessment. 
Lindstedt et al. (1979) too found a significant correlation between individual mercury levels 
in blood in the middle of the week and mean atmospheric mercury levels of the previous 
week. The authors calculated that for atmospheric values of 50 ~tglm
3 ,  the corresponding 
blood mercury values were 30-35 ~tgll, in agreement with the findings of Smith et al. (1970), 
who calculated that for environmental values of 0.10 mg/m
3
,  the corresponding values 
of  blood mercury were 60 ~tgll (group values). 
There was a good correlation between urinary and blood mercury in the study made by 
Smith et al.  (1970), considering group values; a ratio of 0.3 was established between the 
two variables. 
However,  other  studies  did  not find  any  correlationship  between  the  two  parameters 
(Stopford et al.,  1978; Lindstedt et  al.,  1982). 
Stopford et al. (1978) suggested that the relationship between urinary and blood mercury 
could in some way be influenced by the length of exposure and by the different kinetic 
behaviour of the two compartments, even though blood mercury reflects a part of the tissue 
deposits, as demonstrated by the finding of high values of mercury in  blood in  subjects 
no  longer exposed even for six years (Goldwater and  Nicolau,  1966). 
No limit values for  mercury in  blood  have  been  proposed for  occupationally exposed 
subjects. A value of 1 ~tg/1 00 ml was proposed as a "Health evaluation action level" (Miller 
et al., 1975) which should offer protection against subclinical alterations of the central nervous 
system. 
An  increased frequency of abnormalities in  psychometric tests at  blood mercury levels 
between 1 and 2  ~tg/1 00 ml  was found by Roels et al.  (1982). 
The results of an  experimental study on humans with  marked mercury suggest that the 
levels of mercury in blood could be indicators of recent exposure, as distinct from urinary 
mercury, which could be indicative of renal accumulation (Cherian et al.,  1978). Moreover, 
the finding of high levels of mercury in  blood in  subjects no longer exposed for as long 
as six years suggests that a relationship nontheless exists between blood mercury and 
tissue deposits of mercury (Goldwater and  Nicolau,  1966). 40 
Indicators of effect 
In general terms, it should be emphasized that some symptoms, such as anorexia, weight 
loss,  tremor,  insomnia,  were  well  correlated  with  the  degree of exposure,  while  other 
symptoms were less correlated (Smith,  1970). 
As far  as specific indicators of effect are concerned,  it can be said that at the present 
time, no biological tests can be identified which will permit biological monitoring of the 
exposed individual, especially in relation to possible early biochemical lesions, when 
the alterations are still reversible. 
Controversy exists,  however, when a group of exposed workers is under consideration. 
In fact, epidemiological research has, for example, shown that significant correlations exist 
between mercury exposure and inhibition of erythrocyte cholinesterase (Wada et al., 1969; 
Lauwerys and Buchet, 1973). Nevertheless, the data reported in the literature do not agree 
as to the  part played  by the erythrocyte cholinesterases (Faa  et  al.,  1976). 
There has also been evidence of inhibition of membrane (Na+K+)- ATPase of RBCs with 
increase in blood and urinary LDH, especially fractions 4a and 5a (Singerman and Catalina, 
1971). 
The wide dispersion of individual results in fact precludes using the measurement of the 
above enzymes as individual indices of early effects due to inorganic mercury absorption. 
Interest has been aroused by some investigations on populations occupationally exposed 
to mercury vapours, which have confirmed previous statements concerning selectivity of 
accumulation of Hg at the lysosomal level.  Significant increases in the plasmatic activity 
of some lysosomal acid hydrolases (!'-glucosidase, !'-galactosidase, 1'-glucoronidase, N -
acetyl glucosaminidase) were found  in  subjects exposed even to concentrations below 
50 p,g/m
3  (Lauwerys and  Buchet,  1973;  Faa  at  al.,  1976). 
As already mentioned, during chronic exposure to elemental and inorganic mercury, the 
critical organ is the central nervous system, involvement of which is confirmed by various 
symptoms but above all by alterations in psychomotorial performance (Skerfving and Vostal, 
1972). Attempts have been made to evaluate the early signs of these changes in exposed 
persons in  relation to dose indices. 
The tests used include psychometric tests and intellectual function and personality analysis 
of exposed subjects. 
A significant correlation was found between performance in the psychometric tests and 
urinary mercury (Chaffin et al.,  1973). Also the results of mechanical and visual memory 
tests and psychometric ability and personality tests were well correlated with the number 
of times in a year over the last 10 years in which urinary mercury had exceeded 100 p,g/1 
(Forzi  et  al.,  1976). Similarly, the  results  of  psychometric tests were correlated with  the 
number of urinary mercury peaks above 0.5 mg/1  observed in the previous, 3,  6 and 12 
months.  Angotzi  et  al.  (1980)  found  significant  differences  in  perceptive  intelligence, 
psychometric ability and memory tests and in personality tests (especially those on socio-
emotional balance) in a group of subjects who had had urinary mercury levels exceeding 
50 p,g/1  for 3 times in  a year,  compared with  a control  group. 
The neurophysiological studies made by Chaffin et al.  (197  4)  and  Langolf et  al.  (1978) 
showed  a  reduction  in  electromyographic  frequencies  towards  lower  levels  that  was 
correlated with  the increase in  urinary mercury levels. 
The same authors reported an increase in the mean tremour frequencies (studied by means 
of spectral analysis) that was correlated with  urinary mercury levels. 
A  good correlation  was  found  between  alterations  in  electrophysiological  parameters 
(especially velocity conduction) and risk index calculated on the basis of environmental 
mercury concentrations  and  length  of  service  in  workers  of  a chloroalkali  plant  after 
prolonged exposures.  The electrophysiological alterations were well  correlated with  the 
objective signs and symptoms of involvement of the motor neurones (Gilioli et al.,  1976). 
The same study also revealed an earlier appearance of the clinical signs of involvement 
of sensitive nerve fibres. 
Organic Compounds 
Indicators of Dose 
Mercury in blood 
Extremely few data are available on  the concentrations of  mercury in  blood in  workers 
exposed to organic mercury compounds. 
In  a study by Goldwater (1973)  on  7 workers exposed for  six  weeks to methyoxyethyl 
mercury chloride, mean mercury in  blood values of 65 p,g/100 ml (range 34-109 p,g/100 
ml)  were found,  without any clinical  signs or symptoms. 41 
Almost all data on mercury in blood in subjects exposed to organic mercury compounds 
concern non-occupational situations. 
A large mass of data were collected on occasion of collective intoxications occurring in 
the general population caused by consumption of organic mercury compounds with food. 
In  populations of fishermen who consumed fish  containing methyl  mercury (Minamata) 
blood mercury levels up to 60 #-tg/1 00 ml were found without any signs or symptoms that 
could be referred to mercury intoxication (Birke,  1973; Skerfving,  197  4;  Clarkson et al., 
1976). 
In populations intoxicated with cereals treated with organic mercury pesticides, a significant 
correlation was found between mercury in blood and frequency of symptoms of paresthesia 
that was identical to the correlation found between the latter and body burden. 
The concentration threshold of mercury in blood at which paresthesia occurs to a degree 
above the base level was calculated to be between 24 and 48 #-tg/1 00 ml (Bakir et al., 1973). 
From  the  data obtained  in  the  population  of  Niigata,  the  threshold  of  appearance of 
symptoms was found to be between 20 and 40 #-tg/1 00 ml (WHO, 1976). No similar studies 
are available for occupationally exposed subjects. 
Mathematical extrapolation was used in order to transpose the data on collective intoxications 
to the occupational field. It was calculated that the earliest clinical effects, i.e., paresthesia, 
occur at levels of 5 #-tg/kg  body weight per day in the case of consumption with food. On 
the basis of a daily volume of 10m3  of inhaled air at the workplace for 225 working days, 
with  an  80% retention  of mercury products,  the TL  V that  should  correspond to  such 
consumption levels would  be  0.07 mgfm3 (WHO,  1976). 
Mercury in urine 
Very small amounts of MeHg are excreted in the urine and the concentration in  urine is 
easily masked by the inorganic mercury present.  Thus,  mercury in  urine is  not a good 
indicator of internal dose for  MeHg (Berlin,  1979). 
Mercury in the hair 
The hair is an  extremely useful  biological material for evaluation of exposure to organic 
compounds. Methyl mercury concentrates in the hair at a much higher rate than in the 
body or in the blood. A linear correlation was established between total  mercury levels 
in blood and mercury in hair levels, with ratios from 1:300 (Berglund et al.,  1971; Nordberg 
and Skerfving,  1971) to 1:500 (Tsubaki,  1971). Hair levels can therefore be used as an 
indicator of "dose" in the whole body as well  as in the brain,  and are consequently an 
invaluable parameter in the surveillance of exposed general populations. However, since 
hair grows at different rates and can obviously be subject to external contamination, caution 
must be used in evaluating this parameter. For this reason, since external contamination 
is very common  in working environments and since mercury can  bind stably with the 
keratine-SH groups, this method is not suitable for monitoring occupational exposure. 
Nevertheless, the sequential estimation of mercury values in segments of hair measuring 
2.5 em taken from  women involved in the epidemic in  Iraq  (Katzantzis et al.,  1976) has 
provided information on the period of mercury accumulation, which went back to one year 
before the hair samples were taken. 
Conclusions 
The metabolism and toxicology of mercury vapours and inorganic mercury compounds 
differ substantially compared to  organic compounds,  to  which,  moreover,  the general 
population is mainly exposed. Also, the meaning of the biological indicators differs according 
to whether exposure was to inorganic or organic mercury. 
For subjects occupationally exposed to mercury vapours and inorganic mercury the test 
most widely used as an indicator of internal dose is HgU, the levels of which, at least on 
a group basis,  are correlated with the environmental concentrations.  In the most recent 
studies reported, a ratio of 1:1  was established between HgAir measured with  personal 
samplers and HgU in #-tg/1.  The HgU levels are used as indicators of exposure after a latency 
period of between 6 months and one year from the beginning of exposure. After cessation 
of exposure the HgU levels may fall progressively; however, in the brain (the critical organ) 
the mercury levels remain high for a long period of time (years). 42 
Fewer data are available on the reliability of HgB as an indicator of exposure since very 
few studies have been carried out on the subject. 
In some studies a good relationship was found between HgU and HgB values. In exposure 
to organic mercury compounds, the only test generally accepted as valid for biological 
monitoring is HgB, which is a complete indicator of exposure for working populations that 
can integrate the quantity of mercury absorbed by inhalation with the quantity absorbed 
through the skin which,  in the case of organic compounds, is one of the main routes of 
absorption. HgU, however, is of very little value since organic mercury is eliminated with 
urine only to a very limited extent. 
In the present state of knowledge, no indicators are available that are capable of revealing 
a reversible biological effect either for exposure to mercury vapours or to organic mercury 
compounds. 
Needs for  Further  Research 
The following are recommendations for further research, for both organic and inorganic 
mercury exposures: 
evaluation of the relationship between HgAir and HgU and HgB, measuring HgAir with 
personal samplers 
study of the behaviour of HgB and HgU in  relationship to duration of exposure, and 
evaluation of the relationship between HgB, HgU and integrated exposure (dose x time) 
study of the relationship between the indicators of internal dose HgU and HgB and : 
lysosomal-derived plasmatic enzymes 
behavioural test 
- test of early neurological damage. 43 
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Organophosphorus  Pesticides
M. Maroni49 
Summary 
Organophosphorus (OP)  pesticides are widely used as insecticides and herbicides. Ex-
posure concerns manufacturers, formulators, applicators in agriculture and public health, 
and the general population. 
OP pesticides present a serious hazard of acute intoxication. The clinical picture of acute 
OP poisoining is characterized by signs of cholinergic overstimulation of the central and 
peripheral nervous system. Fatalities are due to respiratory failure. The mechanism of acute 
OP  poisoning  consists  of  inhibition  of  acetylcholinesterase  (AchE),  the  enzyme  that 
hydrolyses acetylcholine, at the sites where Ach acts as a neurotransmitter. During acute 
OP  poisoning,  a  marked  inhibition  of  erythrocyte  and  serum  cholinesterases  is  also 
measurable. 
Among the chronic effects of OP exposure, the most prominent is a peripheral neuropathy 
(«delayed neuropathy») which may arise few weeks after an acute poisoning or on chronic 
exposure. The delayed neuropathy is induced only by the limited number of OP pesticides 
which are able to  interact with  a specific esteratic enzyme of the nervous tissue,  called 
«Neuropathy Target Esterase» (NTE). Clinically, the delayed neuropathy is a primarily ax-
onal motor neuropathy involving the long nerves of the limbs, which can lead to paralysis. 
Other chronic  effects  reported  on  OP  exposure concern  the central  nervous system 
(behavioral changes), transient modifications of electromyographic parameters, liver function 
modifications, and other metabolic changes (microsomal enzyme induction and porphyrin 
metabolism modification). However all these effects have been poorly characterized and 
their existence and importance are under question. 
Depending on the conditions of exposure,  OP  pesticides can  be absorbed through in-
halation or percutaneous penetration. Ingestion results from accidental events, poor hygienic 
practices or consumption of food contaminated with  OP  residues. 
OP pesticides containing the P = S bond are not active as such and are activated by the 
organism through oxidation of the thiono group to P = 0.  Inactivation of OP esters is per-
formed through hydrolysis of the lateral chain attached to P, oxidative or enzymatic dealkyla-
tion, or other hydrolytic reactions: the metabolites originated by these reactions are deprived 
of anticholinesterase activity and are eliminated with  the urine within a few hours. 
The assessment of exposure to OP pesticides through biological indicators is fundamen-
tal  and,  in  many cases,  represents the only reliable way to evaluate OP  exposure. The 
use of biological indicators, however, encounters some practical difficulties, related to the 
multiplicity of the OP compounds in use, the discontinuous and various modality of pesticide 
use in different contexts, and the paucity of knowledge and experience on the use of some 
of these  biological indicators. 
Among the indicators of internal dose, the urinary excretion of metabolites is the indicator 
of choice. For a few compounds, including parathion, parathion-methyl and fenitrothion, 
simple methods measuring phenolic derivatives in urine can be used. For the majority of 
the OP's such methods are not available and the measurement of alkyl phosphates in urine 
seems to be the most suitable and appropriate procedure. The analytical method for measur-
ing alkylphosphates in  urine is rather sophisticated and laborious. Some OP's including 
malathion,  in  addition to alkylphosphates give specific urinary metabolites. 
The experience of use of indicators of internal dose for the OP compounds in man is very 
limited and interpretation of the results may be difficult. 
The most important and widely used indicator of exposure to OP  is the measurement of 
blood cholinesterase activity. Red  blood cells and serum contain two different enzymes, 
with different specificity and biological variability. The most appropriate for OP exposure 
monitoring is erythrocyte acetylcholinesterase (AchE). Inhibition of erythrocyte AchE shows 50 
a fair correlation with level of exposure as well as severity of intoxication in exposed sub-
jects.  Data  on  the  relationship  between  AchE  inhibition  and  urinary  excretion  of  OP 
metabolites are available for very few OP  pesticides. 
Cholinesterase activity is related only to the acute toxicity of OP esters to the nervous tissue 
and does not inform about chronic or delayed  neurotoxic effects. 
Based almost exclusively on experimental animal studies, the determination of «neurophathy 
target esterase» activity (NTE) in circulating lymphocytes or platelets has been proposed 
as a test to assess the human risk to develop delayed neurotoxic effects from OP's. This 
test however is still at an experimental phase and further studies are required to allow its 
utilization in  man. 
Very recent investigations have shown that certain OP pesticides may be inducers of liver 
microsomal enzimes or interfere with liver porphyrin metabolism in in vitro systems. If the 
occurrence of these effects is confirmed also in  man,  the evaluation of microsomal en-
zyme induction and the determination of the pattern of urinary or plasmatic porphyrins 
could be  of use as  biological indicators of effects in  the future. 51 
Organophosphorus Pesticides 
Introduction 
Pesticides occupy a special position among the many chemicals to which man can be 
exposed, in that they are deliberately spread into the environment for the purpose of kill-
ing or injuring some form of life. 
Ideally their injurious action should be highly specific for undersirable target organisms 
and innocuous to desirable, non-target organisms. In fact, however, most of the chemicals 
in  use as  pesticides are not highly selective, and organophosphorus (OP)  pesticides do 
not escape this rule.  The lack of highly selective pesticidal action represents a risk both 
for man and other desirable forms of life that coin  habit the environment, thus concern has 
been growing about the side effects on the environment and human health caused by 
an  unrestricted and uncontrolled use of pesticides. 
Organophosphorus esters are one of the most important class of pesticides; they are us-
ed as insecticides and, to a lesser extent, as herbicides. Utilization of OP insecticides oc-
curs in agriculture and in public health application for the purpose of controlling vector-borne 
diseases.  Moreover these compounds are freely available on the retail  market and are 
used in great amounts in gardens, green-houses and indoor plant growth by almost the 
entire population. This greatly enlarges the number of potentially exposed subjects and 
accounts for the number of fatalities and accidental poisonings worldwide recorded every 
year.  Unlike other industrial, man-made chemicals, exposure to OP pesticides may con-
cern a great part of human population,  ranging from the most heavily exposed groups 
(manufacturers, formulators, professional applicators in agriculture or in  public health) to 
the general population which may experience exposure because of domestic use,  prox-
imity to agricultural settings or consumption of contaminated food. 
Despite the magnitude of the problem, knowledge about toxicity of OP pesticides in humans 
is mostly confined to their acute toxic effects. Chronic nervous system damage by these 
compounds has been only recently recognized and investigation on long-term irreversi-
ble effects, such as genetic cell damage or carcinogenicity, is still  embrionic. Biological 
indicators for the evaluation of human exposure to OP's are rather undeveloped and still 
at an experimental phase. With the exception of the measurement of cholinesterase in red 
blood cells and serum, there is only a scarce experience of their use and some tests recently 
developed are not yet applicable on a routine basis because of their complexity and limits 
of interpretability. 
This disappointing picture originates from difficulties which are common to all pesticides. 
First of all,  this class of chemicals comprises numerous different compounds developed 
and marketed to overcome acquired insect resistance. Since each compound has its own 
toxic properties and biological behaviour, this variety of chemicals under continuous change 
makes difficult any acquisitions of consolidated knowledge. Moreover the assessment of 
the relationship between exposure and absorption, which is essential to allow the use of 
any biological indicator of dose,  is  particularly difficult for OP's because many of them 
are absorbed through the skin and techniques of ambient monitoring adopted in the in-
dustrial settings are only very partially usable in agriculture, where the main source of oc-
cupational exposure takes place. Finally, while for acute OP toxicity the biochemical target 
has been identified since long time, investigation about chronic and long-term effects has 
just started and this prevents from a thorough understanding of the relationship existing 
between exposure and biological effects. The body of knowledge, however, is rapidly ex-
panding and, as the evaluation of exposure through biological tests tends to be included FORMULA 
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in every preventive program for agricultural or industrial workers, improvement and stan-
dardization of the methods of monitoring can  be expected in  a near future. 
Chemical and physical properties 
Most of the  phosphorus-containing  insecticides are  derivatives of the  phosphoric and 
thiophosphoric acids and can be represented by the general formula shown in Figure 1, 
Fig.  1 General  structural formula of organophosphorus pesticides. 
where R1 and R2 are either ethyl (C2H5-)  or methyl (CH3-)  substituents. Depending on 
the configuration of the oxigen or sulfur atoms, six main groups of OP's may be distinguish-
ed:  phosphates,  0-phosphorothioates,  S-phosphorothioates,  phosphorodithioates, 
phosphonates and phosphoramidates (Fig. 2).  Each of these groups comprises many in-
dividual compounds. Figures 3 to 7 show the chemical structure and chemica-physical 
properties of some representatives of each  group. 
Fig.  2 General  structural  formula  of  organophosphorus pesticides. 
phosphates  0-phosph orothioates 
phosphorodith1oates  phosphonates 
Fig. 3 Names,  formula and chemica-physical  properties of  some phosphates. 
NAMES 
dichlorvos 
0,0-dimethyi,0-(2,2-dichlorovinyl) phosphate 
mevinphos 
2-methoxycarbonyl-1-methyl-vlnyl 
dimethyl phosphate 
tetrachlorvinphos 
2-chloro-1-(2,4,5-tnchlorophenyl)vinyl 
dimethyl  phosphate 
paraoxon 
0,0-dimethyl-0-p-nltrophenyl  phosphate 
chlorfenviphos 
2-chloro-1-(2,4-dlchlorophenyl)  v1nyl 
dimethyl phosphate 
S-phosphorothioates 
phosphoramidates 
PHYSICAL  SOLUBILITY 
STATUS  IN  WATER 
liquid  1% 
bp 140° 
yellow liqu1d  soluble 
cis 1somer  1  00 t1mes 
more potent 
solid  11  ppm 
mp97-98° 
oily  liquid  0.24% 
bp1  0  170° 
amber liquid  145 ppm Fig.  4 Names,  formula and chemico-physical properties of  some phosphorothioates. 
FORMULA  NAMES 
CH30  S  ,,. 
parathion-methyl 
cH,o/ P'-o0No,  0,0-dimethyl 0-p-nitrophenyl  phosphorothioate 
CH30  ~S 
"~  fenitrothion 
CH3o/ P'-oQNo2  0,0-dimethyl 0-(3-methyl-4-nitrophenyl) 
phosphorothioate 
CH3 
CH
30'-. ;~·  fenchlorphos 
CH30/p'-.  0  Cl  0, 0-dimethyl 0-(2, 4, 5-trichlorophenyl) 
phosphorothioate 
Cl 
C2HsO  ~s 
><o 
parathion 
C2HsO  0  02  0,0-diethyl-0-p-nitrophenyl phosphorothioate 
C2HsO'  _,s 
demeton- 0 
/p' 
0,0-diethyl  0-[2-(ethylthio)ethyl] phosphorothioate  C2HsO  0-CH2CH2S-C2Hs 
C,HsO '-..  ;S  -CN 
diazinon 
P  ,.......cH3 
C2HsO/ 'o I  )-cH  0, 0-diethyl (2-isopropyl-6-methyl-4-pyrimidinyl) 
N  '\.CH3  phosphorothioate 
C2HsO,  _,o 
demeton- S 
/p' 
0,0-diethyl S-[2-(ethylthio)ethyl)  phosphorothioate  C2HsO  S-CH2CH2S-C2Hs 
Fig.  5 Names, formula and  chemico-physical  properties of  some phosphorodithioates. 
FORMULA  NAMES 
malathion 
0,0-dimethyl S-[1 ,2-di(ethoxycarbonyl)ethyl] 
phosphorodithioate 
dimethoate 
0 ,0-dimeth yl  S-(N-methyl-carbamoylmethyl) 
phosphorodithioate 
azinphos-methyl 
0,0-dimethyl S-(3,4-dihydro-4-oxobenzo-[1 ,2,3]-
triazin-3-ylmethyl)  phosphorodithioate 
disulfoton 
0,0-diethyl S-[2(ethylthio)-ethyl]  phosphorodithioate 
phorate 
0,0-diethyl S-[(ethylthio)-methyl]  phosphorodithioate 
phosalone 
0,0-diethyl S-(6-chlorobenzoxazolon-3-yl)methyl 
phosphorodithioate 
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PHYSICAL 
STATUS 
crystals 
mp 37° 
yellow oil 
white powder 
mp 41° 
pale yellow liquid 
bp 375° 
oily liquid 
liquid with  faint 
ester-like odor 
oily liquid 
PHYSICAL 
STATUS 
brown to yellow 
liquid 
crystals 
mp 52° 
crystals 
mp 73° 
colorless oil 
clear liquid 
crystals 
mp 48° 
SOLUBILITY 
IN  WATER 
50  ppm 
practically 
insoluble 
40 ppm 
20  ppm 
practically 
msoluble 
40 ppm 
practically 
insoluble 
SOLUBILITY 
IN  WATER 
145 ppm 
very slightly 
soluble 
33  ppm 
insoluble 
50  ppm 
practically 
insoluble 54 
Fig. 6 Names, formula and chem1co-phys1cal  properties of  some phosphonates. 
FORMULA  NAMES 
PHYSICAL 
STATUS 
CH30""- ~0 
trichlorfon  white crystals  p 
CH30 /  ""-CHOHCCI3  O,O·dimethyl  (1-hydroxy-2,2,2-trichloroethyl)  mp 83-84° 
phosphonate 
c,H,........_  ;s-d- trich loronate 
c2H 5o/P'-o 0  c1  0-ethyl  0·(2  ,4, 5-trichlorophenyl) ethyl 
phosphonothioate 
Cl 
CH30'  -?S  Cl 
()p'~· 
leptophos  waxy solid 
0-methyl 0·(4-bromo-2,5-dichlorophenyl)phenyl  mp 65-67° 
phosphonothioate 
Q;s 
/'0 
EPN  liquid w1th 
C2HsO  0  N02  O·ethyl  0-4-nitrophenyl  phenyl phosphonoth1oate  aromatic odor 
Fig. 7 Names,  formula and chem1co-physical  propert1es of  some phosphoramidates. 
FORMULA  NAMES 
acephate 
O,S·dimethyl  N·acetyl-phosphoram1doth1oate 
methamidophos 
O,S·dimethyl  phosphoramidothioate 
PHYSICAL 
STATUS 
white solid 
mp 64-68° 
crystals 
mp 54° 
Chemical stability of OP esters greatly influences their uses, their environmental persistence 
and the possibility of toxic effects to living organisms. 
One of the most important reactions of OP  insecticides is their hydrolysis by water.  The 
attack can take place at either the phosphorus or the alkyl chain and generally this reac-
tion produces the lost of pesticidal action as well  as toxicity to humans. Susceptibility to 
hydrolysis depends largely on the group attached to the phosphorus. Moreover, because 
P = 0  is  more electrophilic than is  P = S,  any change from S to 0  greatly increases the 
rate of hydrolysis. Water hydrolysis is favoured at an alkaline pH and strong alkali hydrolysis 
can be used to destroy OP  toxicity. 
The oxidation of P =StoP=  0 is another very common and important reaction that occurs 
in both abiotic and biotic conditions. The conversion of phosphorothioates to the homologous 
phosphates greatly enhances their toxicity to  insects and mammals. 
A typical reaction occurring with 0-phosphorothioates is the thion-thiol isomerization under 
the influence of light and temperature. Thus,  0-phosphorothioates are converted into S-
phosphorothioates, which  are in  general more toxic than the  parent compounds. 
Solubility in  water varies greatly from one compound to another.  Most of OP  esters are 
scarcely soluble in  water but some of them are freely soluble and can be formulated in 
water-based  medium. 
It must be remembered that commercial formulations of OP  pesticides may not contain 
only a single compound but rather  be  a mixture of OP's.  Besides deliberately added 
substances, commercial products may also contain production impurities, sometimes in 
remarkable concentrations. The biological behaviour and toxicity to humans of OP associa-
tions may be different from those of the single compounds because metabolic interactions 
may result in  synergic effects (see the example of malathion;  further on  pag.  66). 
SOLUBILITY 
IN  WATER 
soluble 
practically 
insoluble 
practically 
Insoluble 
SOLUBILITY 
IN WATER 
soluble 
soluble 55 
Mechanism of action 
Organophosphorus pesticides exert their biological actions acting as inhibitors of enzymes. 
Esterases (or ester hydrolases) are the target enzymes responsible for OP toxicity to in-
sects and mammalian species. Toxicity of a given dose of an OP compound to an animal 
organism primarily depends on the inhibiting power (affinity) of the OP against esterases 
and on the ability of that organism to activate or inactivate the OP. 
Cholinesterase  inhibition 
Organophosphorus insecticides produce their acute toxic actions by inhibiting cholinesterase 
(ChE),  the enzyme performing the hydrolytic cleavage of acetylcholine into choline and 
acetic acid. This mechanism of action is demonstrated by the fact that many of these com-
pounds are inhibitors of ChE in vitro,  and the inhibition of ChE can be measured in vivo 
after administration of OP insecticides. Additionally, atropine and other cholinergic block-
ing agents protect against acute OP poisoning and reversal of ChE inhibition which may 
be pharmacologically induced in  intoxicated patients with oxime derivatives  , results in 
alleviation of symptoms of poisoning. 
Acetylcholine acts as  a  neurotransmitter of  nerve action  potentials of all  preganglionic 
autonomic fibers, all post-ganglionic parasympathetic fibers and a few post-ganglionic sym-
pathetic fibers. Moreover acetylcholine is the neurohumoral transmitter of the skeletal muscle 
motor end-plates and some interneuronal synapses in  the central  nervous system.  The 
synaptic transmission of nerve potentials requires that acetylcholine is liberated in the in-
tersynaptic space, linked by the postsynaptic receptor and destroyed within milliseconds, 
thus allowing the impulse transmission to end.  This last task is  normally performed by 
acetylcholinesterase (AchE), an enzyme located mainly in the nervous system and in the 
motor plates of skeletal muscle. When AchE is inhibited, post synaptic cholinergic transmis-
sion  is  not  ended  within  the  proper time  and this  results  in  a  protracted  cholinergic 
overstimulation. 
There are two principal types of cholinesterases in  the human organism: 
I.  acetylcholinesterase (other names: acetylcholine acetyl hydrolase (EC 3.1.1. 7.), specific 
cholinesterase,  erythrocyte cholinesterase) and 
II  butyryl-cholinesterase (PchE) (other names:  acylcholine acylhydrolase (EC 3.1.1.8.), 
aspecific cholinesterase,  pseudocholinesterase,  plasma or serum cholinsterase). 
They differ in  location in  tissues,  substrate affinity and physiological function. 
AchE hydrolyzes acetylcholine at a greater velocity than any other choline ester. Besides 
nervous tissue, AchE is also present in erythrocytes, where it is located on the cell mem-
brane. The function of AchE in  red  blood cells is  unknown. 
PchE (or plasma cholinesterase) is a generic term covering a highly inhomogeneous group 
of  enzymes,  sometimes divided into  butyryl  and propionylcholinesterase according to 
substrate affinity.  In  the nervous tissue,  PchE activity is  present in  glyal cells but not in 
neurons. Moreover PchE is present in plasma, liver and some other organs. Its physiological 
function is unknown. In human sera at least 4 isoenzymes have been identified by various 
techniques. In some subjects there is an absolute deficiency of plasma cholinesterase which 
is replaced by an atypical plasma esteratic enzyme. Atypical enzimes are seen in 3% of 
the population together with the normal PchE (heterozigous subjects). Very few subjects 
(homozigous; about 1/1 0.000) have a complete absence of normal PchE, which is entirely 
replaced by atypical variants. Atypical enzymes can be characterized by their inhibition 
pattern (for instance, resistance to dibucaine inhibition). These atypical enzymes are the 
result of genetic modifications in the locus that determines the formation of cholinesterase. 
Practically all the pharmacological effects induced by OP compounds in the organism are 
due  to  the  inhibition  of  AchE  with  the  consequent  accumulation  of endogenous 
acetylcholine. 
PchE is inhibited as well,  but its inhibition at most sites produces no apparent functional 
derangement. 
The mode of interaction of substrates and inhibitors with acetylcholinesterase is schematized 
in Figure 8, which shows the reaction of AchE with the physiological substrate, acetylcholine, 
and an OP insecticide, paraoxon. There are three important steps in the reaction: the first 
is complex formation and is governed by an  affinity constant Ka (K-1  /K1).  This is quite 
small for the OP  insecticides as  well  as for the natural substrate acetylcholine; therefore 
formation of enzyme-substrate or enzyme-inhibitor complex is favoured. With acetylcholine 
K2 and K3 are both very fast so that the total reaction occurs rapidly and new active en-
zyme is  regenerated. With  OP esters K2 is moderately fast,  but K3  is extremely slow, so 
the phosphorylated enzyme accumulates while the amount of reversible complex is minimal 
at any time. 56 
Fig. 8 Reactions of acetylcholinesterase (AchE)  w1th  mhib1tors  or substrates. 
A.  Scheme of the whole react1on. 
B.  Hydrolysis of the physiological substrate acetylcholine. 
C.  Reaction  w1th  paraoxon. 
ENZYME  K1 ENZYME/SUBSTRATE  ACYLATED  K3  ACID 
---l.  ---+  ---+  +  ~  OR  OR  + 
A  SUBSTRATE  K.1 
ENZYME/INHIBITOR  K2  PHOSPHO- ENZYME 
(INHIBITOR) 
COMPLEX  RYLATED 
ENZYME 
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The number of molecules hydrolyzed per minute by one molecule of enzyme has been 
estimated to be 1  Q7 to 1  oa times less for OP compounds than for acetylcholine. Therefore, 
the enzyme rapidly hydrolyzes acetylcholine, but is rather irreversibly inhibited by the OP's. 
The rate of recovery of free and active acetylcholinesterase following  poisoning by OP 
compounds varies with  different compounds, the great majority of OP's leading to long 
but reversible inhibition. Spontaneous reversal  of enzyme inhibition occurs through the 
hydrolysis of the phosphorylated cholinesterase. 
With some compounds a phenomenon known as «aging» of the phosphorylated enzyme 
occurs. Aging consists of a dealkylation of one of the groups linked to the phosphorous 
moiety of the complexes and leaves a hydroxy residue free on the phosphorylated en-
zyme (Figure 9). This reaction is important for the treatment of poisoned patients because 
Fig.  9 Ag1ng  of phosphorylated acetylcholinesterase (AchE). 
the capacity of the oxime derivatives to reverse cholinesterase inhibition in vivo depends 
on whether or not such reaction has already taken place. Since the «aged» phosphorylated 
enzyme cannot be reactivated by the oxymes, the effectiveness of treatment with these 
substances in  antagonizing the poisoning is directly correlated with the earlyness of ad-
ministration and inversely related to the  rate of aging of the single OP  compounds. 
«Neuropathy Target Esterase» Inhibition 
Delayed neurotoxic action of some OP pesticides is independent of cholinesterase inhibi-
tion but related to the phosphorylation of a specific esteratic enzyme in the nervous tissue, 57 
which has been denominated «neurotoxic esterase» or «neurophathy target esterase» (NTE) 
(1 ). The sequence of biochemical events at the receptorial site leading to the development 
of the delayed neuropathy has been in part elucidated (Figure 1  0). The initial biochemical 
Fig.  10 Events triggering organophosphorus-Induced delayed neuropathy. 
(I)  phosphorilation of NTE 
(II)  aging of OP-NTE complex  B
o_ 
11/0 
0-P  + 
"-o-R 
(Ill)  ? 
reaction is  represented  by the phosphorylation of NTE.  An  essential second step is the 
transformation of the phosphorylated target to an «aged» form in which one group attach-
ed to the phosphorus has been cleaved and a negatively charged residue remains at-
tached to the protein. The occurrence of this aging reaction,  which is analogous to the 
aging of AchE-OP complexes, depends only on the chemistry of the OP  and may only 
occur  with  phosphates,  phosphonates  and  phosphoramidates.  Compounds such  as 
phosphinates and carbamates are not able to age (Figure 11) and if they link to NTE before 
Fig.  11  Anticholinesterase agents may be neurotoxic or  protect1ve for delayed neuropathy according to 
whether they can  age or not. 
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an axonopathic OP is administered, they block the receptor preventing the development 
of the neuropathy (2). 
Identification of NTE and evidence for a direct involvement of this enzyme in the delayed 
neuropathy was achieved from animal experiments demonstrating the selective binding 
of labelled axonapathic OP's to an esteratic protein in the nervous tissue (3,  4).  Since the 
nervous tissue contains a number of esteratic enzymes and none of them has an absolute 
specificity of substrate, the activity of NTE can be isolated and measured in the nervous 
tissue only after suppressing other irrelevant esteratic enzymes. This can be partially per-
formed by administering an OP compound such as for instance paraoxon (POX), which 
is  a  potent inhibitor of AchE  and  many other esterases  but does not cause  delayed 
neuropathy. If one administers an adequate dose of paraoxon to an animal species sen-
sitive to delayed neuropathy (usually the hen),  AchE is  strongly inhibited and the total 
esteratic activity of the nervous tissue decreases to less than 500/o,  but the animal is still 
sensitive to develop delayed neuropathy if dosed with an  axonopathic compound. This 
indicates that NTE  belongs to the fraction of POX-resistant esterases. 
On the other hand, after administering an axonopathic OP (for instance, mipafox or DFP, 
diisopropylfluorophosphate), some esteratic activity is still detectable in the nervous tissue 
and this indicates that there are esteratic enzymes which are resistant to both paraoxon 
and mipafox or DFP (5). 
NTE may be biochemically defined as the esteratic activity which remains after inhibition 
of nervous tissue esterases by non-axonopathic OP's and which is sensitive to inhibition 
of  axonopathic compounds (6).  Figure 12 shows the fractioning of esterase activity of the 
rat brain tissue which is obtained through the selective inhibition with a non-axonopathic 
OP (paraoxon) followed by an  axonopathic one (mipafox). (7). 
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Fig.  12 Phenylvalerate-hydrolyz1ng esterase fract1ons  of rat  bra1n  accordmg to  paraoxon (40 ,uM)  or paraoxon 
plus m1pafox  (40 ,uM  +  50 ,uM)  1nhlblt1on 
Different animal species are not all equally sensitive to develop delayed neuropathy from 
OP's. Within each species, susceptibility varies with age, young animals being almost totally 
resistant (1). The animal model of choice for the investigation of delayed neuropathy from 
OP's has been the hen. In order to cause delayed neuropathy in the hen, a minimum NTE 
inhibition of 70% in vivo has to be reached within 24 hours after OP administration. Whether 
a threshold exists in humans too and what its value is, is not known as yet, nor is it known 
what happens to the neurons as a consequence of the above reactions involving NTE. 
The esteratic activity itself of NTE may not be considered a biochemical function indispen-
sable to the health of neurons as it may be suppressed without provoking neurophathy. 
Defective protein synthesis or impaired axonal flow have been conjectured as  putative 
mechanisms of the delayed neuropathy,  but no experimental evidence supports these 
hypotheses. 
The physiological function of NTE,  if any,  is unknown. In man NTE is present in the ner-
vous tissue,  in  liver,  in  lymphocytes, in  platelets and in  other tissues.  (8). 59 
Experimental studies in the hen have indicated that,  after administration of axonopathic 
OP's, inhibition of NTE in  blood lymphocytes correlates with  NTE inhibition in central as 
well  as peripheral nervous tissue.  (9,  1  0).  As will  be further on detailed, this observation 
has lead to the attempt to develop biological indicators for monitoring the human risk of 
delayed neuropathy from  OP's. 
Effects of OP  pesticides on  humans 
Acute  Effects 
The OP pesticides present a serious hazard of acute intoxication which varies considerably 
from compound to compound. The TD50 of OP's in mammals vary from mg tog/kg body 
weight (30).  Some OP's are not active as such but need to be activated in the organism. 
Symptoms and signs of acute OP intoxication are given in Table I (36).  When only local 
exposure occurs, signs and symptoms may be confined to the site of contact and spare 
the rest of the organism. The immediate cause of death in fatal OP poisoning is asphyxia 
resulting from  respiratory failure. 
Table 1.  Signs and symptoms of  anticholinesterase poisoning 
S1te  of  action 
Pupils 
C1l1ary  body 
Conjunctivae 
Mucous membranes 
Bronchial tree 
Sweat glands 
Striated  muscle 
Bronchial tree 
Gastrointestinal system 
Sweat glands 
Salivary glands 
Lacrimal glands 
Pupils 
Ciliary body 
Bladder 
Striated  muscle 
SympathetiC ganglia 
Central  nervous system 
Circulatory system 
(from  36.  modified) 
Signs and symptoms 
LOCAL EXPOSURE 
Pin-point miosis 
Frontal  headache,  eye pain,  dimness of  vision 
Hyperaemia 
Rhinorrhoea,  hyperaemia 
Tightness in  chest with  prolonged wheezing,  bronco-constriction and 
increased secretion,  cough 
Sweating at  the  s1te  of  contact 
Fasciculat1ons  at  site  of  contact 
SYSTEMIC ABSORPTION 
Tightnees in  chest with  prolonged wheezing,  broncho-constriction, 
increased secretion,  dyspnoea,  slight pain  1n  chest,  cough 
Anorexia,  nausea,  vomiting,  abdominal cramps,  epigastric and 
substernal tightness,  eructation,  diarrhoea,  tenesmus,  involuntary 
defecation 
Increased sweating 
Increased salivation 
Increased lacrimation 
Slight miosis (occasionally unequal),  later marked 
Blurring  of  vision 
Frequent or involuntary micturition 
Fatigue,  weakness,  muscular twitching, fasciculations,  cramps, 
generalized weakness including muscles of respiration with 
dyspnoea and cyanosis 
Pallor,  occasional elevation  of  blood pressure 
Giddiness,  tens1on,  anx1ety,  jitteriness,  restlessness,  emotional  lability, 
excessive dreammg,  insomnia,  nightmares,  headache, tremor,  apathy, 
Withdrawal  and depression,  bursts of slow waves of elevated  voltage in 
EEG  especially on  hyperventilation, confusion,  slurred speech,  ataxia, 
convulsions,  coma 
Bradycardia,  decreased cardiac output,  cardiac arrest.  paralysis of 
vasomotor centre 
The interval between exposure and the onset of symptoms may be as short as a few minutes 
or last some hours. The duration of symptoms is generally from 1 to 5 days and in  non-
fatal cases symptomatology may subside without leaving permanent sequelae. Onset and 
duration of the acute phase as well  as severity of the pois,oning may vary with the route 
of exposure and the absorbed dose, and differ markedly for different compounds accor-
ding to their rate  of biotransformation and affinity for cholinesterase. 60 
Confirmation of the nature of the poisoning is usually achieved by the finding of a marked 
inhibition of erythrocyte or plasma cholinesterase. 
Chronic or delayed effects 
The great majority of the OP compounds in  use are  rapidly metabolized and excreted, 
and subacute or chronic poisoning due to accumulation of the compounds in the organism 
does not occur. However, because several OP compounds cause slowly reversible inhibi-
tion of cholinesterase, accumulation of this effect can occur. Thus,  signs and symptoms 
resembling those occurring after a single high dose may be produced by repeated small 
doses absorbed on  chronic exposure. 
Certain OP pesticides can also produce a delayed neuropathy which is totally indepen-
dent of their cholinesterase-inhibiting power. This neuropathy is the same as that caused 
by other organophosphorus esters such  as  triorthocresylphosphate (TOCP)  which  are 
deprived of anticholinesterase activity and not used as pesticides (11 ).  The pathological 
and clinical picture of delayed neuropathy from OP pesticides is well known in animals (12). 
In man only a limited number of cases have been reported, but numerous epidemics of 
peripheral neuropathy involving thousands of subjects have been described for TOCP (11, 
13). 
Delayed neuropathy from OP's may occur both as a sequela of acute intoxication or after 
prolonged exposure. Clinical onset of the neuropathy occurs 1 to 3 weeks after exposure. 
The main symptoms, cramping muscle pain and progressive weakness, begin in the legs 
with ascending progression and may eventually involve the arms. Subjective sensory loss 
is  typically mild  or  absent.  On  examination,  depression of tendon reflexes and flaccid 
weakness of the distal limb muscle are the outstanding signs. Mild to moderate pyramidal 
signs may be present as well.  The  pathological picture is typical of a distal axonopathy 
with proximally progressive nerve degeneration. Axonal lesions primarily involve the large-
diameter fibers of the long nerves of the limbs and the long spinal cord tracts, particularly 
in the dorsal columns. Electromyographic examination of these patients reveals a pattern 
of partial denervation of the affected muscles and electroneurography shows an appreciable 
delay in  terminal motor latencies while maximal  motor conduction velocity is  normal or 
very slightly decreased in  most cases.  Recovery from  the neuropathy is very slow and 
may be incomplete as indicated by the observation of functional impairments still lasting 
years after the onset of the neuropathy (14). 
Numerous OP pesticides are able to induce delayed neuropathy in experimental animals 
and the structure-activity relationship has been in part identified (2).  So far human cases 
have  been  reported  after exposure to  mipafox  (15),  leptophos (16),  trichlorphon  (17), 
trichloronate (18),  and methamidophos (19). 
Investigations on workers exposed to OP pesticides during their manufacture have also 
shown  transient  modifications  of  some  electromyographic  and  electroneurographic 
parameters (20, 21). These findings however have not been confirmed in extended studies 
and their significance has been questioned. 
Persistent central nervous system alterations have been sometimes described in patients 
recovering from acute OP intoxication as well as in subjects chronically exposed to OP's 
(23-26).  Impaired vigilance and reduced concentration,  slowing of psychomotor speed 
and information processing, memory deficit, linguistic disturbance, depression, anxiety and 
irritability have been the most frequently reported behavioral changes. Although the studies 
available on human behavioral changes by OP pesticides are incomplete and sometimes 
inconsistent, they indicate an area warranting more systematic and definitive investigation. 
In surveys on workers exposed to OP's alone or in combination with other pesticides, ab-
normalities of blood chemistry parameters or serum enzymes other than PchE have been 
occasionally described. However there is no rigorous epidemiological evidence that these 
effects have to  be  attributed to  OP  exposure on  a cause-effect  basis.  In  animals,  OP 
pesticides show a low-to-moderate liver toxicity and toxic liver injuries are not a common 
finding in  human acute intoxications. Therefore liver deserves much less emphasys as a 
target organ of OP  toxicity,  than is  usually laid  on  it. 
Recent investigations have shown that several OP pesticides, including parathion, diazinon, 
chlorfenviphos and azinphosmethyl, can induce porphyrinogenic effects in experimental 
conditions (27). Human cases of porphyria have been reported after exposure to diazinon 
and dicrotophos (28). 
OP  pesticides have always been considered to be only inhibitors of enzymes.  However 
a study on exposure to malathion during its production has documented a shortening of 
antipyrine half-life in the workers (29).  This would suggest that OP compounds may also 
be inducers of liver microsomal enzymes. 61 
Metabolism 
Absorption and  distribution 
OP pesticides may enter the organism through inhalation, ingestion and percutaneous ab-
sorption. The relative importance of these routes of entry varies according to the physico-
chemical properties of the OP, the exposure condition, and the nature of the formulation 
of the pesticides. 
Inhalation is mainly important during the production of pesticides in chemical plants, their 
formulation  and their diffusion by aerial spray. 
Percutaneous absorption may occur especially during formulation when the pesticides are 
improperly handled, or during application in agriculture or in  public health.  Ability of the 
different OP's to penetrate the skin varies from one compound to another but is generally 
enough to produce acute intoxication if the operators are not adequately protected. Specific 
studies on skin penetration of the different OP's in animals and man are available and the 
subject has been  recently  reviewed (30). 
Absorption of OP's through the digestive tract has been demonstrated by reports of acute 
intoxications following oral ingestion in man. Digestive tract absorption due to occupational 
exposure may occur when personal hygienic practices are poor or workers consume food 
in  contaminated areas.  This  route of absorption is  also  relevant to the possibility of OP 
intake by the population as a consequence of consumption of vegetables or fruits con-
taminated with  OP  residues. 
Investigations with different OP's have shown that the bioavailability of their active forms 
in the organism is less after digestive absorption than after other routes of exposure. This 
is explained by the «first pass»  phenomenon, that is the greater inactivation occurring in 
the liver as compared with other tissues when the compounds pass through this organ 
before accessing distribution via the general circulation. 
After absorption, OP pesticides and their metabolites distribute quickly in all tissues. The 
maximum concentrations are usually found in liver and kidney; lipophilic compounds may 
reach  remarkable concentrations in  nervous tissue or other lipid-enriched tissues. 
Plasma half life of OP  pesticides after single administrations ranges from minutes to few 
hours, depending on the compound and the route of administration. For some compounds 
there is a marked interindividual and inter-species variation in biokinetics; for this reason, 
the extrapolation of animal  data to man must be cautious. 
Biotransformation 
The relationship between enzymatic biotransformation and toxicity of OP pesticides is ex-
tremely complex. 
Toxicity depends upon the net availability of active compound to inhibit the specific en-
zymatic targets at critical sites in nerve tissue, and this in turn depends upon the dynamic 
relationships  between activation and inactivation reactions. 
Activation.  All thiono OP pesticides, that is those containing a P = S bond, are not active 
inhibitors of AchE, but require activation by oxidation of the P =  S to the P =  0 group, thus 
producing the corresponding oxygen analogues (Figure 13). 
Fig.  13 Act1vat1on  of phosphoroth1oates and phosphorodith1oates 
parath1on  paraoxon 
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The enzyme system in  liver that catalyzes this reaction belongs to the group of NADPH-
dependent mixed-function oxidases of the microsomes. Although the liver has the greatest 
capacity to perform this reaction, this bioactivation may also occur in other tissues, including 
lung and brain. Activation of thiono OP compounds by extrahepatic tissues,  even if only 
in  minimal amounts, may be of importance if these tissues are critical target organs for 
AchE inhibition. 
Inactivation. Detoxification of OP pesticides in the organism can occur either by biochemical 
modifications of their structure or by their linkage to binding sites of the organism having 
no toxicological significance. 
The main reactions yelding products deprived of anti-ChE  activity are: 
1  .  breakage of the P-X  bond by esterases; 
2.  oxidation of the alkyl side chain (R1 or R2) so that the R-0-P bond becomes unstable 
and breaks; 
3.  transfer of the alkyl  group to  glutathione by the action of glutathion S-transferase; 
4.  breakage of ester bonds by carboxylesterases. 
The first reaction may be exemplified with the biotransformation of parathion (Figure 14). 
Fig.  14 Metabolic pathways of parathion. 
p-nitrophenol  p-n1trophenol 
diethylthiophosphate  diethylphosphate 
Parathion after conversion to its oxygen analogue, paraoxon, is hydrolized with formation 
of free p-nitrophenol. Hydrolysis of paraoxon is performed by an enzyme, paraoxonase, 
which  is  present  in  serum,  liver  and  other tissues  of  animals and the  man.  The  aryl-
phosphorus bond can also be cleaved without prior oxidation of parathion to paraoxon. 
This reaction is catalyzed  by a NADPH-dependent microsomal enzyme which appears 
to be distict from the enzyme that converts parathion to paraoxon. The rate at which this 
oxidative cleavage or the combined oxidation-hydrolysis occurs, determines the amount 
of paraoxon available in  tissues for the inhibition of AchE. 
Dealkylation reactions, either oxidative or through the action of glutathion alkyltransferase, 
occur to only a very minimal extent with parathion, but are very important for several other 
compounds. 
Oxidative dealkylation is performed by the microsomal system of the liver. For some OP's, 
such  as  for instance chlorfenviphos,  inactivation by this reaction  is substantial  (31). 
Since there is a marked interspecies variation of the relative rate of this system, acute tox-
icity of chlorfenviphos in  different animal  species is strictly dependent on the efficiency 
of this detoxificating pathway. 
Other  compounds,  including  methylparathion  and  azinphosmethyl,  are  preferentially 
monodealkylated by glutathion alkyltransferase (32), the activity of which is influenced by 
the availability of liver glutathion. 
Hydrolysis of ester or amidic bonds located in the lateral chains of the molecule is an im-
portant inactivation reaction for compounds such  as  malathion and dimethoate (Figure 
15). This reaction is carried out by tissue or plasma carboxylesterases (or carboxylamidases) 
and the products of hydrolysis are not inhibitors of cholinesterase. Since carboxylesterases 
are serine-esterases which can be inhibited by other OP compounds, combined exposure 
to different OP  pesticides may potentiate the acute toxicity of malathion by blocking its Fig.  15 Metabolic pathways of malathion. 
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detoxification (33, 34). Such a phenomenon is believed to have occurred in Pakistan where 
in 1978 an acute epidemics of malathion poisoning affected thousands of people working 
for a malaria control program. The epidemics broke out when a brand of malathion con-
taminated with  iso-malathion and other minor impurities was used.  As malathion per se 
is one of the safest OP pesticides for man, the cause of the mass poisoining was attributed 
to the metabolic potentiation of its toxicity through the inhibition of carboxylesterases in-
duced by the  impurities (35). 
All  the reactions discussed above may be considered true inactivation mechanisms,  in 
that the active OP compounds are biotransformed with formation of less active or totally 
inactive metabolic products. There is  another major mechanism of detoxification which 
does not operate through metabolic conversion of the OP but rather by sequestering the 
active forms of the OP's at binding sites of the liver and other tissues. These binding sites, 
which are very likely represented by non-specific tissue esterases, may exert a great buf-
fer capacity, thus sparing the critical AchE  of nerve tissue from  inhibition. 
Elimination 
Elimination of OP's and their metabolites occurs mainly via the urine and the faeces,  be-
ing fecal  elimination mediated through  hepatic transport into the  bile. 
Urinary and fecal  excretion is usually rapid. With  most compounds 80-90% of the dose 
is eliminated within 48 hours, although small amounts of OP's and their metabolites can 
be recovered in  urine for a few days. 
A very little proportion of the OP's and their active forms (the oxons) is eliminated unchanged 
in  the  urine. 
The  by  far  largest  part  of  the  compounds  present  in  excreta  is  represented  by 
alkyl phosphates and the residues resulting from the hydrolysis of the specific groups at-
tached to the posphorus. Rate of elimination and relative proportion of each metabolite 
varies over time and with  different compounds. 
More detailed information on the metabolism and the specific products of elimination of 
some OP's in  man will  be found  in  Table 6. 64 
Biological  indicators 
In recent years, while advances in analytical chemistry have offered improved possibilities 
of measuring pesticides and their metabolites in the organism, comparatively less progress 
has been made in the acquisition of early and reversible indicators of their toxicity in humans. 
On the other hand, the wider availability of analytical possibilities itself has seldom resulted 
in concrete improvements of routine monitoring because problems of cost and the multiplicity 
of products handled by agricultural or public health workers hamper its practical application. 
Human exposure to pesticides has different characteristics according to whether it occurs 
during their industrial production or their use (Table 2) (35). The formulation of commercial 
Table 2.  Comparison between exposure characteristics during production and use  of  pesticides. 
Duration  of  exposure 
Degree of  exposure 
Type of exposure 
Skin  absorption 
Ambient monitoring 
Biological monitoring 
(from  35,  modified) 
Exposure on  production 
Continuous and  prolonged 
Quite constant 
To  one or few compounds 
Easy to  control 
Useful 
Complemental to  ambient 
monitoring 
Exposure on  use 
Vanable and intermittent 
Extremely variable 
To  numerous compounds either 
in  sequence or concomitantly 
from  use  of  mixtures 
Variable according to  work 
procedures 
Seldom  Informative 
Very  useful  when  available 
products by mixing active ingredients with other coformulants, has some similarities with 
use as far as exposure characteristics are concerned. In fact these activities are typically 
performed by small industries which manufacture many different products in subsequent 
campaigns. Thus, the workers are exposed to several pesticides and to each of them for 
a short time.  In public health and agriculture, the usage of a variety of compounds is general-
ly the rule, although in some specific applications (for example, cotton defoliation or malaria 
control  programs) a single product may be used. 
Usage of biological indicators of exposure is particularly necessary in pesticide utilization 
where the conventional techniques of ambient monitoring are scarcely applicable. Moreover, 
the possibility of percutaneous absorption makes the use of biological indicators very im-
portant to assess the level  of exposure in  every circumstances. 
Indicators of internal dose 
For the majority of OP pesticides, the blood or urine concentration of the substance itself 
or its metabolites represent an  indicator of exposure.  However,  in  order to use plasma 
or urine concentrations as indicators of internal dose, metabolism and pharmacokinetics 
of each compound should be known with reference to studies in humans, since extrapola-
tion from animal species to man can be only tentative and qualitative. 
Although other routes of elimination are active, the determination of metabolites in the urine 
is the most practical mean for the estimation of the internal dose of the OP pesticides. Tak-
ing into account the general features of the OP biotransformation, two complemental ap-
proaches may be used: the determination of metabolites deriving from the alkylphospate 
moiety of the molecule or the measurement of the lateral-chain residues which are generated 
by the hydrolysis of the P-X  bond. 
Both these methods have been attempted, but a variable success has been achieved for 
different compounds, according also to the analytical methods used. 
The measurement of p-nitrophenol in  urine to assess the internal dose of parathion has 
been among the oldest tests developed. Favoured by the availability of colorimetric analytical 
methods, this test  has been widely experimented and has  proved to  be  successful  in 
evaluating exposure to parathion (30).  Parathion-methyl and EPN are other pesticides which 
yeld p-nitrophenol in urine (37).  Exposure to fenitrothion may be surveyed by measuring 
p-nitrocresol  in  urine (38). 
Less experience has been obtained with OP's bearing other chemical structures in  the 
lateral chain. The measurement of the product of hydrolysis of the P-X bond seems to be 
analitically  rather  easy  when  the  metabolic  residues  to  be  detected  are  phenolic  or 65 
chlorophenolic derivatives, as  in  the case of chlorfenviphos or fenchlorphos.  When the 
metabolites originating from the cleavage of the P-X bond are complex heterocyclic struc-
tures, as occurs f.i. with azinphos-methyl, or non-specific chemicals as occurs with malathion, 
this approach cannot be  successfully pursued. 
The alternative consists of measuring alkylphosphates in  urine. The rationale for the use 
of this method resides in the fact that metabolism of most OP's yelds alkylphosphates or 
alkyl(di)thiophosphates as terminal products. Since these metabolites are common to several 
different OP's, this method is not compound-specific and is only usable to assess exposure 
to all  the parent compounds which  may generate these derivatives. This fact,  if advan-
tageous when multiple exposure has to be monitored, represents a limit for the toxicological 
interpretation of results, because each OP pesticide has its own metabolic rate and toxici-
ty level. The various alkylphosphates detectable in urine and the main parent compound 
they can originate from,  are listed  in  Table 3. 
Table 3.  Organic phosphates detectable in  urine as  metabolites of  OP  pesticides 
Metabolite 
Monomethylphosphate 
(MMP) 
Dimethyl phosphate 
(DMP) 
Diethylphosphate 
(DEP) 
Dimethylthiophosphate 
(DMTP) 
Diethylthiophosphate 
(DEPT) 
Principal  parent compounds 
Malathion 
Dichlorvos,  trichlorfon,  mevinphos,  malaoxon.  dimethoate, 
fenchlorphos 
Tetraethylpyrophosphate,  paraoxon,  demeton-oxon,  diazinon-oxon, 
dichlofenthion 
Fenitrothion,  fenchlorphos,  malathion,  dimethoate 
Diazion,  demeton,  parathion,  fenchlorphos 
Dimethyldithiophosphate  Malathion,  dimethoate,  azinphos-methyl 
(DMDTP) 
Diethyldithiophosphate  Disulfoton,  phorate 
(DEDTP) 
Phenylphosphonic acid  Leptophos,  EPN 
The  measurement  of  alkylphosphates  in  urine  requires  analytical  methods  rather 
sophisticate, based on derivatization of the compounds and separation and detection by 
GLC (39,  40).  So  far the measurement of alkylphosphates has been  performed in  few 
studies,  mostly addressed to research  purposes. 
With some OP pesticides, the assessment of the internal dose may be performed by deter-
mining urinary metabolites which result from  a partial  degradation of the molecule at a 
site  other than  the  phosphorus bonds.  For  instance,  the  major urinary metabolites of 
malathion are the mono- and dicarboxylic phosphorus-containing acids deriving from the 
hydrolysis of the diethylsuccinic ester in  the lateral  chain (35). 
Knowledge about the relationship between exposure and the internal dose of OP's as deter-
mined by urinary metabolites measurement, is very limited. With the exception of parathion 
and few other compounds, no data are available in humans. Some information has been 
obtained from animal studies,  but the routes of exposure used in these experiments are 
hardly representative of human exposure conditions,  especially as far  as  occupational 
exposure is concerned. To date this is the major drawback against the use of these bioin-
dicators. 
Some studies have investigated the relationship between level of urinary OP metabolites 
and  serum  or  red  blood cell  AchE  activity  in  humans.  Detectable amounts of  urinary 
metabolites without evidence of AchE depression have been found in some cases (30). 
This indicates that biological assessment of exposure through  urinary metabolite deter-
mination may be a very sensitive method, capable of revealing exposure in  a range of 
doses which are insufficient to bring about a toxic response. This very important feature 
accounts for the interest in this methodology despite its practical and analytical difficulties. 
OP metabolites are usually excreted in the urine within a short time and the peak of emis-
sion occurs few hours after the beginning of exposure. 
Therefore in occupational exposure samples collected soon after the end of the work are 
suitable for metabolite determination when 24 hour urine collection is impractical. When 
using spot specimens, creatinine or specific gravity should be determined in order to select 
and discard those samples which  are too diluted or concentrated. 
Trace amounts of alkylphosphates have been found in some studies in the urine of sub-
jects considered non-exposed to OP's (39,41 ).  However, since endogenous sources of 66 
alkylphosphates  others  than  OP  esters  have  never  been  reported,  the  presence  of 
alkylphosphates in urine should be highly specific for OP exposure. According to the Na-
tional Human Monitoring Program of the U.S.  Environmental Protection Agency, the fre-
quency of occurrence of dialkylphosphate residues in the urine of the general population 
is rather low (Table 4) (42).  Until more definite knowledge on this matter is acquired, com-
parison with reference groups or with individual pre-exposure values is recommended when 
surveying workers with  occupational exposure. 
Table 4.  Occurrence of dialkyl  phosphate residues  1n  human unne 
Dialkyl  phosphate residuea.b 
Dimethyl phosphate (DMP) 
Diethyl  phosphate (DEP) 
Dimethyl phosphorothionate (DMTP) 
Diethyl  phosphorothionate (DETP) 
Dimethyl phosphorodithioate (DMDTP) 
Diethyl  phosphorodithioate (DEDTP) 
a)  Based on  analysis of 5676 spec1mens collected in  U.S.A.  on  1976-1980. 
b)  Limits of  detection: 20 ppm. 
(from 42,  modified) 
Indicators  of  effect 
Frequency of 
detection,  % 
12 
7 
6 
6 
The receptors for the toxic action of OP pesticides reside in the nervous tissue and are 
not accessible for being measured with  non-invasive methods. 
Therefore, for the purpose of human biological monitoring, other indicators which are related 
to the receptors in  the nervous tissue and are easily obtainable,  must be used. 
1)  Red  blood cell and  serum cholinesterases. 
Cholinesterase inhibition is the most prominent pharmacodynamic effect of exposure to 
OP  pesticides. 
It must be noted that cholinesterase inhibition is relevant only to acute toxicity of OP's and 
thus the assessment of cholinesterase inhibition is  not by itself predictive of chronic or 
delayed effects. 
The  determination  of  acetylcholinesterase  activity  in  red  blood  cells  (AchE)  or 
pseudocholinesterase activity in serum or plasma (PchE) have been the most reliable and 
widely used indicators of exposure. 
A large and consistent body of evidence indicates that depression of red blood cell AchE 
activity as well  as serum PchE  activity is highly correlated with  intensity and duration of 
single OP exposures. Red blood cell AchE, being the same molecular target as that respon-
sible for acute OP toxicity in the nervous system, is an indicator more specific than PchE. 
Some OP compounds such as for example malathion,diazinon and dichlorvos, are earlier 
inhibitors of PchE than AchE (30). With these substances serum PchE determination might 
be a more sensitive indicator of exposure than AchE;  however PchE inhibition may not 
be associated with  symptoms or signs of toxicity. 
After a single OP exposure, serum PchE activity recoveries more quickly than AchE activi-
ty in  red  blood cells.  After a severe intoxication, the reduction of enzyme lasts up to 30 
days in plasma and up to 100 days in erythrocytes, corresponding to the time of liver PchE 
resynthesis and  red  cell  replacement,  respectively. 
lnterindividual coefficients of variation in cholinesterase activity of the general population 
have been determined in the region of 15-25% for the PchE and 10-18% for erythrocyte 
AchE (43-47). Corresponding figures for intraindividual variation are 60/o and 3-7% respec-
tively. 
Erythrocyte AchE shows no difference in activity between the sexes when the sex-related 
difference in red-cell packed volume is taken into consideration (45-47). There is no signifi-
cant variation with age, with the exception of the less than 6 month old infants who have 
values lower than  adults.  (47-48). 
Plasma Pche shows normal values 10-15% greater in  males than in females. Significant 
correlations have been found between PchE activity and body mass or serum cholesterol 
level (49, 50) and a multifactorial equation has been proposed to predict individual PchE 
values in  healthy subjects based on  physiological individual  parameters (50). 67 
No correlation has been observed between PchE activity and age.  (51). 
Repeated seasonal and circadian measurements of AchE and PchE in healthy subjects 
have not shown any periodical intra-individual variation.  (47,  51). 
A reasonable correlation exists between red cell and plasma AchE activity and the clinical 
signs of the acute intoxication. 
The correlation tends to be better as the rate of inhibition is faster. When inhibition occurs 
slowly and repeatedly, as it happens on chronic or repeated exposure, the correlation with 
illness may be low or totally inexistent.  For instance,  after continuous exposure, clinical 
signs of intoxication may appear only at inhibition of 85-90% of the pre-exposure AchE 
level as opposed to the 60-70% inhibition level usually observed after a single exposure. 
Table 5 summarizes the correlation existing between severity and prognosis of acute OP 
intoxication and the levels of AchE inhibition determined in  peripheral blood. 
Table 5.  Severity and prognosis of  acute OP  intoxication at  different levels of AchE  inhibition 
%AchE  Level  of 
Clinical symptoms  Prognosis 
inhibition  poisoning 
50-60  Mild  Weakness,  headache,  dizz1nes.  nausea,  salivation,  Convalescence 
lacrimation,  miosis,  moderate bronchial spasm  in  1-3 days 
60-90  Moderate  Abrupt weakness,  visual  disturbances, excess  Convalescence 
salivation,  sweating,  vomiting,  diarrhoea,  bradycardia,  in  1-2  weeks 
hypertonia, tremor of hands and head,  disturbed gait, 
miosis,  pain in  the chest,  cyanosis of the  mucous 
membranes 
90-100  Severe  Abrupt tremor,  generalized  convulsions,  psychic  Death  from 
disturbance,  intensive  cyanosis,  oedema of  the  lung,  coma  respiratory  or 
cardiac failure 
Quantitative relationships between exposure or absorbed dose and the effect of some OP's 
on cholinesterase in human subjects are given in Table 6. Studies with volunteers mostly 
cover oral administration and provided gastrointestinal absorption is complete and rapid, 
relationships can be calculated. Exposure to pesticides in manufacturing and application 
environments,  however, involves respiratory and percutaneous absorption, mainly. The 
dose absorbed then should be estimated from air concentration and duration of exposure, 
taking also into account the opportunity for skin absorption. However, such estimates are 
rarely available and little is known on the influence of the route of exposure on metabolism 
of each pesticide. 
The validity of testing cholinesterase activity in monitoring human OP exposure is limited 
because of the natural variation of blood cholinesterase activity in healthy people and the 
occurrence of false positive or negative results. Physiological variation as well as specifici-
ty are more favourable in AchE than in PchE use. The sensitivity of the test can be increas-
ed by adopting individual pre-exposure values as a reference. 
Low values of PchE not related to OP exposure may be found in liver diseases (hepatitis, 
icterus, cirrhosis), uraemia, cancer, hearth failure and allergic reactions. In females, lower 
values are also measured during menstruation and pregnancy. 
Increased  values  of  PchE  are  present in  hypertyroidism  and  other conditions of high 
metabolic rate. 
With AchE, abnormally low values not related to OP exposure have been observed in sub-
jects affected  with  leukemias or other  neoplasmas.  Increased values may be found  in 
polycythemia and in  thalassemia or other congenital blood dyscrasias.  (52). 
Sampling of blood depends on the purpose of the test and on the analytical procedure 
to be used. Venipuncture, although requiring trained personnel, should be preferred even 
when small samples suffice for determination of enzyme activity, because capillary blood 
from a finger or ear-lobe can be unproportionally contaminated with the chemical residing 
on the skin in occupationally exposed subjects. Every time it is possible, three sequential 
samples should be taken before exposure in order to establish a normal baseline for each 
worker. 
·Many analytical methods are available for the determinations of AchE and PchE.  Most 
of them yeld comparable results,  but accuracy and precision vary from one method to 
another. 
Some methods have a sensitivity scale different from others,  so that a given percentage 
of inhibition of a method may not be coincident in term of absolute activity with the same 
percentage of inhibition measured with  a different technique. 68 
Table 6. Available information in man on the relationship between exposure or internal dose of OP compounds and the effects on cholinesterases 
Time course and/or  Exposure-dose and 
Maximum acceptaple 
Compound 
Urinary metabolites 
recovery of  urinary  dose-effect  No-effect  level 
daily 1ntake  (mg/kg 
detected  in  man (a) 
elimination  relationship 
body weight)  and year 
established  {b} 
Azinphos- DMP,  DMTP  (83)  i.v.-1 ,5% after  12  hrs  20 mg/man/day-oral  0.0025 (1974) 
methyl  (57,  58,  59) 
Chlorfen- Desethylchlorv1nphos  oral-4, 7% DEC  at  120 p.g  DEC/24  hrs  0.002 (1972) 
vinphos  (DEC)  (60)  2,5 mg/man/day;  urine excretion  after 
23.8% DEC  after  2.5 mg/man/day for 
12.5 mg/day (60)  53  days (60) 
Chlorpyrifos  DEP,  DETP,  3,5,6-trichloro- 0.03  mg/kg/day-oral  0.01  (1983) 
2-pyridinol  (61 ,62)  (63) 
Demeton  40% PchE  and  16%  0.05 mg/kg/day-oral  No adi  (1983) 
AchE  depression  (64) 
after  0,1  mg/kg/day 
for 25  days (64) 
Diazinon  60% PchE  depression  0.02 mg/kg/day  0.002 (1976) 
and unchanged  (65) 
AchE  after 0.05 
mg/kg/day for 28 
days (65) 
Dichlofenthion  2,4-dichlorophenol (66) 
Dichlorvos  DMP,  dichloroethanol (67)  29% PchE  depression  Thereshold for 
and unchanged  inhibition of PchE 
AchE after 2 mg/  without AchE 
man/day for 28  inhibition: 
days (68,69)  0.15 mgfm3 for 
16 hrs 
0.4 mgfm3 for 5 
hrs (30) 
Dimethoate  70-1 00% excreted  0.2 mg/kg/day (70)  0.002 (1985) 
within 24 hrs (71) 
Fenitrothion  3-methyl-4-nrtrophenol  (38)  Peak excretion after  5 mg/hr excreted after0.33 mg/kg/day (38)  0.003 (1983) 
DMTP (82)  12 hrs;  total  amount  1  0 mg oral  dose (38) 
excreted within 24 
hrs (38) 
Malathion  Malathion monocarboxyl1c  No decrease in  ChE  16 mg/day (73)  0.02 (1978) 
~~  ;,.  '  acid (MCA),  malathion  at 3.6 mg/1  MCA 
dicarboxylic acid (MDA),  in  unne (35, 72);  25% 
DMP,  DMTP,  DMDTP  PchE decrease after 
(30,35)  oral 24 mg/day for 
56 days (73) 
M  eth idath ion  In  rats  DMP and DMTP (74)  0.11  mg/kg/day (75)  0.005 (1976) 
Mevinphos  DMP (76)  Excretion  completed  25% AchE  decrease  1 mg/day (77)  0.0015 (1973) 
within 48 hrs (76)  after  oral  2.5  mg/day 
for 27 days (77) 
0.4 mg/1  DMP in  a 
•.  "'~  '  case of moderate 
poisoning (76) 
Parathion  p-nltrophenol,  DEP,  DETP,  86% p-nitrophenol  1,5 mg/1  0.07 mg/kg/day (79)  0.005 (1979) 
(37,78)  and DETP  excreted  paranitrophenol 
within 8 hrs;  DEP  in  urine at  the end 
persists in  urine for  of the work day 
48 hrs (37)  corresponds to a 
5  mg/man/day  intake 
(30);  89% AchE and 
63% PchE  reduction 
after oral  7.2  mg/ 
man/day (79) 
Parathion- p-n1trophenol,  DMP (37)  60% paranitrophenol  37% AchE  reduction  22  mg/day (80)  0.001  (1979) 
methyl  excreted within  4  after oral 30 mg/day 
hrs;  DEP  excretion  (80) 
more protracted (37) 
Trichlorfon  Dichlorvos,  dichloroethanol  1-10 mg/kg/day  0.01  (1979) 
(81)  (30) 
(a)  for abbreviations see Table 3 
(b)  from  the «Report  of  the Joint FAO/WHO Meetings on  Pesticide Residues  in  Food»,  yearly publrshed by WHO. 69 
Calibration and comparability among different methods should be established in the same 
laboratory and among different settings. At a 1984 WHO meeting it was established that 
a modified version of the Ellman spectrophotometric method should serve as a reference 
for the multinational epidemiological study on  neurotoxic effects of OP  exposure which 
is  being conducted in  Europe under the coordination of the Office for Europe of WHO 
and the sponsorship of United Nations Development Programme (53).  Recently paper-
test methods have also been developed for screening purposes and field use in agriculture. 
These methods, though only semiquantitative,  have low cost and ease of  application. 
Table 7 shows the values of AchE fitting the guidelines for biological monitoring establish-
ed at the Workshop on Epidemiological Toxicology of Pesticide Exposure held in Amster-
dam in  1971  (54). 
Table 7.  Values  of AchE  Inhibition  according to  the criteria for  biological  monitoring  established 
at  the Workshop on  Epidemiological Toxicology of  Pesticide Exposure (Amsterdam,  1971) 
Level  Significance 
AchE 
Measures required 
Inhibition  (a) 
First level  Values at  which  no  physiological  No action needed 
(no effect)  or biochemical effects are 
expected. 
Values  usually found in  normal 
population without exposure 
Second  Values indicative of or  0-30 (1)  Medical surveillance needed. 
level  compatible w1th  minor and  0-50 (2)  Working conditions to  be 
(surveillance)  reversible effects  examined to avoid exceeding 
such  a level 
Third level  Values indicative of  or  30-60 (1)  Temporary removal from  exposure 
(effect)  compatible with  minor damages  50-70 (2)  and analysis of working conditions 
(initial  symptoms,  mild  needed 
alterations of sensitive 
clinical  indexes) 
(a)  By definition,  any «effect test»  cannot evaluate the first  level. 
(1)  Based on individual  pre-exposure baseline. 
(2)  Based on normal reference values. 
2)  Lymphocyte and  platelet NTE. 
The onset of delayed neurotoxic effects induced by some OP compounds has been shown 
to be preceded by inhibition of «Neuropathy Target Esterase» (NTE) in the nervous tissue 
immediately after exposure. Since NTE is present in circulating lymphocytes and platelets, 
the measurement of peripheral NTE  might be informative of the events occurring in the 
nervous tissue of subjects exposed to OP esters. 
Experimental data have indicated that after dosing animals with axonopatic OP's NTE in-
hibition measured in peripheral lymphocytes parallels inhibition in the central and peripheral 
nervous tissue (Figure 16) (9).  In the first few hours after administration, the levels of NTE 
inhibition in  blood and nervous tissue are almost coincident, while in the following days 
the rate of recovery of NTE activity is slightly more rapid in lymphocytes than in the peripheral 
nerves,  due to different rates  of NTE  re-synthesis (Table 8)  (55). 
The existence of such a correlation has prompted the experimental testing of this method 
in subjects exposed to axonopathic OP's. Lotti and coworkers, monitoring cotton-defoliant 
sprayers, have found a consistent inhibition of activity in blood lymphocytes in the absence 
of any detectable sign of illness (56). The NTE activity decrease occurred during and after 
exposure and was preceded in some subjects by a transient increase in NTE activity soon 
after the beginning of exposure (Figure 17). The meaning of this diphasic phenomenon, 
which  sometimes has also been observed in  experimental animals,  is still  unknown. 
This pilot application suggests that this method of monitoring may be promising to assess 
the risk of delayed neurotoxic effect. So far this test is still  at a developmental stage and 
definite criteria of interpretation of the results in man are not yet available.  Moreover the 
test presents inherent complexities, including the analytical method required for NTE assay 
in  blood lymphocytes. Since a fair correlation has been observed between NTE activity 
in human lymphocytes and platelets (Figure 18), substituting platelets for lymphocytes may 
facilitate the application of the method (7). The reference values for NTE activity determin-
ed in two independent studies are shown in  Table 9 (7,  22,  84).  Further experience on 
the validity of this approach as well as on the criteria of interpretation of the results needs 
to  be  acquired before this method can be properly exploited in  field applications. 70 
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DFP  adminstration. 
Table 8.  Neurotoxic esterase activity followmg  Intramuscular administration of  DFP  1n  the hen 
Neurotoxic esterase activity (b) 
Time after 
DFP  injection (a)  Lymphocyte  Brain 
Sp1nal  Penpheral 
cord  nerve 
4 hr  4  2  7  15 
8 hr  12  3  6  8 
12  hr  10  4  8  14 
24  hr  34  8  12  16 
48  hr  39  15  17  25 
72  hr  63  24  19  28 
96  hr  76  33  26  41 
7 day  91  42  37  44 
9 day  70  45  44  72 
14  day  107  79  71  97 
(a)  DFP  dose:  1  .4  mg/kg 
(b)  Percentage of baseline act1v1ty.  Means of 4 animals.  (from  55) 71 
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Table 9.  Reference  values of  lymphocyte and  platelet  NTE  activity in  different groups of  subjects 
No  Lymphocytes  Platelets 
Location  of  (nmol.min-1.mg prot-1)  (nmol.min-1.mg prot-1)  Ref. 
subjects  Mean  so  Mean  so 
Baltimore,  68  13.2  2.4  8.4  1.5  7 
USA 
Valtellina,  35  11.9  3.0  8.5  1.9  84 
Italy 
Padova,  108  11.5  2.5  22 
Italy 
Conclusions 
The assessment of exposure to OP pesticides through biological indicators represents the 
only reliable way to evaluate OP exposure in many cases. The use of biological indicators, 
however, encounters some practical difficulties, related to the multiplicity of the OP com-
pounds in use, the discontinuous and various modality of pesticide use in  different con-
texts, and the paucity of knowledge and experience on the use of some of these biological 
indicators. 
Among the indicators of internal dose, the urinary excretion of metabolites is the indicator 
of choice. For a few compounds, including parathion, parathion-methyl and fenitrothion, 
simple methods measuring phenolic derivatives in urine can be used. For the majority of 
the OP's, such methods are not available and the measurement of alkylphosphates in urine 
is  the most suitable and appropriate procedure.  The  analytical  method for  measuring 
alkylphosphates in  urine  is  rather  sophisticated  and  laborious.  Some  OP's,  including 
malathion,  in addition to alkylphosphates give specific urinary metabolites. 
The experience of use of indicators of internal dose for the OP compounds in man is very 
limited and interpretation of the results may be difficult. 
The most important and widely used indicator of exposure to OP pesticides is the measure-
ment of blood cholinesterase activity. Red blood cells and serum contain two different en-
zymes,  with  different specificity and biological variability. 
The most appropriate for OP exposure monitoring is erythrocyte acetylcholinesterase (AchE). 
Inhibition of erythrocyte AchE shows a fair correlation with  level of exposure as well  as 
severity of intoxication in exposed subjects. Data on the relationship between AchE inhibi-
tion and urinary excretion of OP  metabolites are available for very few OP  pesticides. 
Cholinesterase activity is related only to the acute toxicity of OP esters to the nervous tissue 
and does not inform about chronic or delayed neurotoxic effects. 
Based almost exclusively on experimental animal studies, the determination of «Neuropathy 
Target Esterase» activity (NTE) in circulating lymphocytes or platelets has been proposed 
as a test to assess the human risk to develop delayed neurotoxic effects from OP's. This 
test however is still at an experimental phase and further studies are required to allow its 
utilization in  man. 
Very recent investigations have shown that certain OP pesticides may be inducers of liver 
microsomal enzymes or interfere with liver porphyrin metabolism in in vitro systems. If the 
occurence of these effects is confirmed also in man, the evaluation of microsomal enzyme 
induction and the determination of the pattern of urinary or plasmatic porphyrins could 
be of use as  biological indicators of effect in  the future. Bibliographic  references 
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